|
¢ã¤³¤Îµ»ö¤ÎÏ¢ºÜÌܼ¡¤Î¥Ö¥í¥°¢ä¡¡https://blogs.yahoo.co.jp/kikitata3/35907064.html
¹ñºÝƬÄËʬÎà(Âè3ÈÇ) Ìõ¡§ÆüËÜÆ¬Ä˳زñ¡¦¹ñºÝƬÄËʬÎà°Ñ°÷²ñ¡¡
ƬÄË¿ÇÎŤËÌòΩ¤Ä¹ñºÝʬÎࡦ¿ÇÃÇ´ð½à¤ÎºÇ¿·ÈÇ¡ª
¹ñºÝƬÄ˳زñ¤¬ºîÀ®¤·¤¿Æ¬ÄˤÎʬÎࡦ¿ÇÃÇ´ð½à¤¬¡¢¤Ä¤¤¤ËÀµ¼°¤ÊÂè3ÈǤˡ£Á°ÈǤ«¤é¡¢Â¿¤¯¤Î¼ÂÃϻ¤ò·Ð¤Æ¡¢¥¨¥Ó¥Ç¥ó¥¹¤¬¶¯²½¤µ¤ì¤Þ¤·¤¿¡£·ø¤¤¸«¤¿Ìܤʤ¬¤é¡¢¸¦µæ¤Ï¤â¤Á¤í¤ó¡¢Î×¾²¤Ë¤ª¤¤¤Æ¤â¤è¤¥Ñ¡¼¥È¥Ê¡¼¤Ë¤Ê¤ë¤³¤ÈÀÁ¤±¹ç¤¤¡£¿ÇÃǤ˺¤¤Ã¤¿¤é¤¼¤ÒËܽñ¤ò°ú¤¤¤Æ¤ß¤Æ¤¯¤À¤µ¤¤¡£ÌòΩ¤Ä¥Ò¥ó¥È¤¬¤¿¤¯¤µ¤ó¤¢¤ë¤Ï¤º¡£¿À·ÐÆâ²Ê°å¡¢Ç¾¿À·Ð³°²Ê°å¡¢Áí¹ç¿ÇÎŰå¤Ë¤È¤Ã¤Æ¤Ï¡ØËýÀƬÄˤοÇÎÅ¥¬¥¤¥É¥é¥¤¥ó¡Ù¤È¤È¤â¤Ë¼ê¸µ¤ËÃÖ¤¤¤Æ¤ª¤¯¤Ù¤1ºý¡£ ¹ñºÝƬÄËʬÎà¡¡Âè3ÈÇ¡ÊICHD-3¡ËÆüËܸìÈǤ˴󤻤ơÊJes Olesen¡Ë¡¿¹ñºÝƬÄËʬÎà¡¡Âè3ÈÇ¡ÊICHD-3¡ËÆüËܸìÈÇ¡¡ºîÀ®¤Ë¤¢¤¿¤Ã¤Æ¡ÊÃÝÅ翲ìÉס¦À¶¿å¡¡ÍøÉ§¡Ë¡¿¸¶½ñÂè3ÈǤνøÊ¸¡ÊJes Olesen¡Ë ¹ñºÝƬÄËʬÎà¡¡Âè3ÈÇ¡ÊICHD-3¡ËÆüËܸìÈÇ¤Ë´ó¤»¤Æ Foreword ICHD-3 It is a great pleasure for me to welcome this Japanese translation of the International Classification of Headache Disorders, third edition. We owe credit to our Japanese colleagues for their continued dedication to the improvement of the diagnosis and therefore also treatment of headache disorders. This field is often somewhat disregarded, but migraine alone is number six among diseases causing disability. In terms of cost to society headache disorders are number three after dementia and stroke among neurological disorders. In the past there was not enough emphasis on a precise headache diagnosis, but this was improved after the advent of the first edition of this classification in 1988. Today we know that the treatment of headache disorders is very different from one diagnosis to the next. Furthermore, the amount of laboratory investigation also depends a lot on the clinical diagnosis. It is therefore my hope that this Japanese translation of ICHD-3 will gain widespread use in Japan. Courses in headache diagnosis for neurologists and general practitioners would be very useful and could perhaps be organized by the Japanese Headache Society. ¡¡¹ñºÝƬÄËʬÎà¡¡Âè3ÈÇ¡ÊICHD-3¡Ë¤ÎÆüËܸìÌõ¤¬°ìÈ̸ø³«¤µ¤ì¤ë¤³¤È¤ÏÂ礤ʴî¤Ó¤Ç¤¹¡£¤ï¤ì¤ï¤ì¤ÎÆüËܤÎÃç´Ö¤¬Æ¬ÄËÀ¼À´µ¤Î¿ÇÃǤȼ£ÎŤβþÁ±¤ËÀ䤨´Ö¤Ê¤¤ÅØÎϤò³¤±¤Æ¤¤¤ë¤³¤È¤ò¾Î»¿¤·¤Ê¤±¤ì¤Ð¤Ê¤ê¤Þ¤»¤ó¡£¤³¤ÎÎΰè¤Ï¤·¤Ð¤·¤Ð·Ú»ë¤µ¤ì¤Þ¤¹¤¬¡¤ÊÒÆ¬ÄˤϤ¹¤Ù¤Æ¤Î¼À´µ¤Î¤¦¤Á¡¤Ã±ÆÈ¤ÇÂè6ÈÖÌܤ˻پã¤ò¤¤¿¤·¤¦¤ë¤â¤Î¤Ç¤¹¡£¼Ò²ñÁ´ÂΤΰåÎÅÈñ¤Î¥³¥¹¥È¤È¤·¤Æ¤Ï¡¤Æ¬ÄËÀ¼À´µ¤Ï¤¹¤Ù¤Æ¤Î¿À·Ð¼À´µ¤Î¤¦¤Á¡¤Ç§ÃξɤÈÇ¾Â´Ãæ¤Ë³¤¯Âè3ÈÖÌܤμÀ´µ¤Ç¤¹¡£ ¡¡²áµî¤Ë¤ÏÀµ³Î¤ÊƬÄË¿ÇÃǤνÅÍ×À¤¬½½Ê¬¶¯Ä´¤µ¤ì¤Æ¤¤¤Þ¤»¤ó¤Ç¤·¤¿¤¬¡¤1988ǯ¤Ë¹ñºÝƬÄËʬÎà¤Î½éÈǤ¬È¯´©¤µ¤ì¤Æ¤«¤é¡¤²þÁ±¤µ¤ì¤Æ¤¤Æ¤¤¤Þ¤¹¡£º£Æü¡¤¤ï¤ì¤ï¤ì¤ÏƬÄËÀ¼À´µ¤Î¼£ÎŤ¬¡¤¤½¤Î¿ÇÃǤˤè¤êÂ礤¯°Û¤Ê¤ë¤³¤È¤òÃΤäƤ¤¤Þ¤¹¡£¤µ¤é¤Ë¤Þ¤¿¡¤¸¡ºº¥Ç¡¼¥¿¤Ë´Ø¤¹¤ë¸¦µæ¤ò¤É¤ì¤À¤±»Ü¹Ô¤Ç¤¤ë¤«¤âƬÄˤÎÎ×¾²¿ÇÃǤ˺¸±¦¤µ¤ì¤Æ¤¤¤ë¤Î¤Ç¤¹¡£¤·¤¿¤¬¤Ã¤Æ¡¤ICHD-3ÆüËܸìÈǤ¬ÆüËܤǹ¤¯ÉáµÚ¤·»ÈÍѤµ¤ì¤ë¤³¤È¤¬»ä¤Î˾¤ß¤Ç¤¹¡£¤ª¤½¤é¤¯¡¤º£¸å¡¤ÆüËÜÆ¬Ä˳زñ¤Ë¤è¤Ã¤Æ´ë²è¤µ¤ì¤ëƬÄË¿ÇÃǤ˴ؤ¹¤ë¶µ°é¥³¡¼¥¹¤Ï¡¤¿À·ÐÆâ²Ê°å¡ÊƬÄËÀìÌç°å¡Ë¤ä°ìÈ̳«¶È°å¤Ë¤È¤Ã¤ÆÈó¾ï¤ËÍÍѤǤ¢¤ë¤È»×¤ï¤ì¤Þ¤¹¡£ ¹ñºÝƬÄËʬÎà¡¡Âè3ÈÇ¡ÊICHD-3¡ËÆüËܸìÈÇ¡¡ºîÀ®¤Ë¤¢¤¿¤Ã¤Æ ËÝÌõ¤Î·Ð°Þ ¡¡¹ñºÝƬÄËʬÎàÂè2ÈÇ¡ÊICHD-2¡Ë¤¬2004ǯ¤Ë´©¹Ô¤µ¤ì¡¤À¤³¦³Æ¹ñ¤Ç³Æ¸À¸ì¤ËËÝÌõ¤µ¤ì¹¤¯»ÈÍѤµ¤ì¤Æ¤¤¿¡£¤ï¤¬¹ñ¤Ç¤â¡¤´ÖÃæ¿®ÌéÍý»ö¡ÊÅö»þ¡Ë¤ò°Ñ°÷Ĺ¤È¤·¤ÆËÝÌõºî¶È¤¬¿Ê¤á¤é¤ì¡¤2004ǯ¤ËÆüËܸìÈǤ¬¸ø³«¤µ¤ì¡¤¤ï¤¬¹ñ¤ÎƬÄ˰åÎŤ¬Â礤¯¿ÊŸ¤·¤¿¡£ ¡¡¤½¤Î¸å¡¤WHO¤ÎICD-11¤ÎºöÄê¤Ë¸Æ±þ¤·¤Æ¹ñºÝƬÄËʬÎàÂè3ÈǤκîÀ®¤Ë¸þ¤±¤Æ¡¤Olesen°Ñ°÷Ĺ¤Î²¼¡¤¹ñºÝƬÄ˳زñ¡ÊIHS¡Ë¤ÎƬÄËʬÎà°Ñ°÷²ñ¤¬³èư¤ò³«»Ï¤·¤¿¡£ÆüËܤ«¤é¤ÏÃÝÅ礬ÊÒÆ¬ÄˤΡ¤Ê¿ÅŬ°ìÍý»ö¤¬¶ÛÄ¥·¿Æ¬ÄˤΡ¤ºä°æÊ¸É§ÂåɽÍý»ö¡ÊÅö»þ¡Ë¤¬´¶À÷¾É¤Ë¤è¤ëƬÄˤΡ¤¤½¤ì¤¾¤ìworking-group¤Ë»²²Ã¤·¤Æ²þÄûºî¶È¤¬¿Ê¤á¤é¤ì¤¿¡£2013ǯ¤Ë¹ñºÝƬÄËʬÎàÂè3ÈÇbetaÈÇ¡ÊICHD-3¦Â¡Ë¤¬¸ø³«¤µ¤ì¤¿¡£¤³¤ì¤ò¼õ¤±¤ÆÆüËÜÆ¬Ä˳زñ¤ÏËÝÌõ¤Î¤¿¤á¤Î¾ïÀ߰Ѱ÷²ñ¤È¤·¤Æ¡¤¹ñºÝƬÄËʬÎà°Ñ°÷²ñ¤ò2013ǯ¤ËÀßÃÖ¤·¤¿¡£ICHD-3¦Â¤ÏICHD-2¤Ë²ÃÉ®½¤Àµ¤¹¤ë·Á¤ÇºîÀ®¤µ¤ì¤Æ¤ª¤êÆüËܸìÈÇICHD-3¦Â¤ÏICHD-2ÆüËܸìÈǤò´ð¤Ë¤·¤Æ¡¤Êѹ¹Éôʬ¤òÄɲÃËÝÌõ¤¹¤ë¤³¤È¤ò¸¶Â§¤È¤·¤¿¡£³Æ¾Ï1¡Á3̾¤Î°Ñ°÷¤Çʬô¤·¤ÆÆüËܸìÈǤòºîÀ®¤·2014ǯ¤Ë´©¹Ô¤·¤¿¡£2018ǯ1·î¤Ë¤Ï¡ØCephalalgia¡Ù»ï¤Ë¹ñºÝƬÄËʬÎàÂè3ÈÇ¡ÊICHD-3¡Ë¤¬·ÇºÜ¤µ¤ì¤¿¤Î¤Ç¡¤Æ±°Ñ°÷²ñ¤ÇÆüËܸìÈǤò²þÄû¤·½ÐÈǤ¹¤ë¤³¤È¤ò·èÄꤷ¡¤¤¿¤À¤Á¤Ëºî¶È¤ò³«»Ï¤·¤¿¡£ ¡¡¤Þ¤º¡¤ICHD-3¦Â¤«¤éICHD-3¤Ø¤Î¼çÍפÊÊѹ¹ÅÀ¤ò³Æ¾Ï¤ÎôÅö¼Ô¤¬Àººº¤·¡¤¼çÍץݥ¤¥ó¥È¤ò¤Þ¤È¤á°Ñ°÷²ñ¤È¤·¤ÆÆ¤µÄ¤·¡¤¡Ö¹ñºÝƬÄËʬÎàÂè3ÈǸø³«¤Î¤´°ÆÆâ¡×¤È¤·¤ÆÊѹ¹ÅÀ¤Ë¤Ä¤¤¤ÆÆüËÜÆ¬Ä˳زñweb site¤Ë·ÇºÜ¤·¤¿¡Êhttp://www.jhsnet.org/information/20180409_info.html¡Ë¡£ ¡¡°Ñ°÷²ñÀìÍѤΥ᡼¥ê¥ó¥°¥ê¥¹¥È¤òÍøÍѤ·¡¤Ìõ¸ì¡¤ÍѸì¤ÎÁªÂò¤äËÝÌõ¤Î¤·¤«¤¿¤Ê¤É¿ï»þ°Õ¸«¸ò´¹¤·¤Ê¤¬¤é¡¤ËÝÌõºî¶È¤òʬô¤·¤Æ¿Ê¤á¤¿¡£Ê¬Ã´¤Ë¤Ä¤¤¤Æ¤ÏICHD-3¦ÂËÝÌõ¤ÎºÝ¤ÎôÅö¤ò¤½¤Î¤Þ¤Þ°ú¤·Ñ¤°¤³¤È¤È¤·¤¿¡Êɽ¡Ë¡£2018ǯ6·î3Æü¡ÊÆü¡Ë¤ª¤è¤Ó6·î24Æü¡ÊÆü¡Ë¤ËµÙÆü¤òÊ־夷¤Æ¡¤Ã´Åö°Ñ°÷¤È¥³¥¢¥á¥ó¥Ð¡¼¤òÃæ¿´¤Ë½ªÆü°Ñ°÷²ñ¤ò³«ºÅ¤·brush-upºî¶È¤ò¹Ô¤Ã¤¿¡£¤µ¤é¤Ë¡¤¥á¡¼¥ê¥ó¥°¥ê¥¹¥È¤òÍøÍѤ·¤Æbrush-upºî¶È¤ò¿Ê¤á¡¤Æ±Ç¯10·î1Æü¤Ë¥Ñ¥Ö¥ê¥Ã¥¯¥³¥á¥ó¥È¤òµá¤á¤ë¤¿¤á¤ËÆüËÜÆ¬Ä˳زñweb site¾å¤Ë·ÇºÜ¤·¡¤¤³¤ì¤ËʹԤ·¤Æ½ÐÈǤΤ¿¤á¤Î¹»Àµºî¶È¤ò¿Ê¤á¤¿¡£¹»Àµºî¶È¤Ï¡¤³Æ¾Ï¤ÎôÅö°Ñ°÷¤¬Ã´ÅöÉôʬ¤Î¹»Àµ¤ò¹Ô¤¤¡¤Á´ÂΤι»Àµ¤ÈÄ´À°¤ÏÃÝÅç¡Ê°Ñ°÷Ĺ¡Ë¡¤À¶¿å¡ÊÉû°Ñ°÷Ĺ¡Ë¤È¡¤¸Þ½½Íòµ×²Â°Ñ°÷¡¤¼ÆÅĸî°Ñ°÷¡¤±ÊÅıɰìϺ°Ñ°÷¤¬¥³¥¢¥á¥ó¥Ð¡¼¤È¤·¤Æ¼Â»Ü¤·¤¿¡£°å³Ø½ñ±¡¤ÎÊÔ½¸¼Ô¤Î¶¨ÎϤâÆÀ¤Æ¡¤¹»Àµºî¶È¤ò·«¤êÊÖ¤·¹Ô¤¤ICHD-3¤ÎËÝÌõºî¶È¤ò´°Î»¤·¤¿¡£ ɽ¡¡¼Â̳°Ñ°÷¤ÎËÝÌõʬô
¹ñºÝƬÄËʬÎà¤È¿ÇÃÇ´ð½à¤Î°ÕµÁ ¡¡¹ñºÝƬÄËʬÎà¤È¿ÇÃÇ´ð½à¤Î°ÕµÁ¡¤½ÅÍ×À¤Ï·«¤êÊÖ¤·ÏÀ¤¸¤é¤ì¤Æ¤ª¤ê¡¤¼þÃΤΤ³¤È¤Ç¤Ï¤¢¤ë¤¬¡¤¤³¤³¤ÇºÆÅ٥ݥ¤¥ó¥È¤ò½Ò¤Ù¤Æ¤â¡¤¶¯Ä´¤·¤¹¤®¤È¤¤¤¦¤³¤È¤Ï¤Ê¤¤¤Ç¤¢¤í¤¦¡£ ¡¡1988ǯ¤Î½éÈǤǤÏÊÒÆ¬ÄˤοÇÃÇ´ð½à¤¬½é¤á¤Æ¼¨¤µ¤ì¤¿¤³¤È¤Ë¤è¤ê¡¤¤½¤ì¤Þ¤Ç¸¦µæ¼Ô¤ä»ÜÀß¡¤¹ñ¤Ë¤è¤Ã¤Æ¤µ¤Þ¤¶¤Þ¤Ç¤¢¤Ã¤¿¡ÖÊÒÆ¬ÄˡפμÀ´µ³µÇ°¤¬Åý°ì¡¤É¸½à²½¤µ¤ì¡¤Æ±¤¸ÅÚɶ¤ÇÊÒÆ¬ÄˤÎÉÂÂ֤伣ÎÅË¡¤¬ÏÀ¤¸¤é¤ì¤ë¤è¤¦¤Ë¤Ê¤Ã¤¿¡£¤½¤Î·ë²Ì¡¤Î×¾²»î¸³¤Ï½¾Á°¤è¤ê¤µ¤é¤Ë²Ê³ØÅª¤ÊÊýË¡¤Ç¸úΨŪ¤Ë¿Ê¤á¤é¤ì¤ë¤è¤¦¤Ë¤Ê¤Ã¤¿¡£ÆüËܸìÈǺîÀ®¤Ë¤¢¤¿¤êµ¿µÁ¤¬À¸¤¸¤¿¾ì¹ç¤Ï¹ñºÝƬÄËʬÎà°Ñ°÷²ñ¤Ë¾È²ñ¤·¿Ê¤á¤¿¤¬¡¤¤½¤Î¤ä¤ê¤È¤ê¤Î¤Ê¤«¤Ç¡ÖWe are all ¡Èspeaking the same language¡É¡×¤È¤¤¤¦É½¸½¤¬¤¢¤ê¡¤Æ±¤¸ÄêµÁ¡¦ÍѸì¤ÎÍý²ò¤Ë´ð¤Å¤¤¤Æ¿ÇÎŤ並µæ¤ò¹Ô¤¦½ÅÍ×À¤¬¶¯Ä´¤µ¤ì¤Æ¤¤¤¿¤³¤È¤¬°õ¾ÝŪ¤Ç¤¢¤Ã¤¿¤Î¤Ç¤³¤³¤Ëµ¤·¤Æ¤ª¤¤¿¤¤¡£¤Þ¤¿¡¤¿À·Ð²Ê³ØÅª¡¤¿À·ÐÀ¸Êª³ØÅª¡¤Ê¬»Ò°äÅÁ³ØÅª¤ÊƬÄ˸¦µæ¤Î¿ä¿Ê¤Ë¤â´óÍ¿¤·¡¤ÊÒÆ¬Äˤò¤Ï¤¸¤á¤È¤¹¤ëƬÄËÀ¼À´µ¤ÎÉÂÂÖÍý²ò¤¬¿Ê¤ó¤À¡£ ¡¡2004ǯ¤ÎICHD-2¤Ç¤Ï¡¤ËýÀÊÒÆ¬ÄË¡ÊChronic migraine¡Ë¤¬Äɲ䵤졤½éÈǤǸ¶°øÊª¼Á¤ÎËýÀÀݼè¤Þ¤¿¤ÏÇøÏª¤Ë¤è¤ëƬÄË¡ÊHeadache induced by chronic substance use or exposure¡Ë¤È¤·¤ÆµºÜ¤µ¤ì¤Æ¤¤¤¿Æ¬Äˤ¬¡¤ÌôʪÍðÍÑÆ¬ÄË¡ÊMedication-overuse headache¡Ë¤È¤·¤Æ³µÇ°¤¬À°Íý¤µ¤ì¤¿¡£¤³¤ì¤Ï¡¤È¿ÉüÀ¤ÎÊÒÆ¬ÄˤÎɸ½àŪ¤Ê¼£ÎŤ¬³ÎΩ¤·¡¤ÊÒÆ¬Ä˼£ÎŤβÝÂ꤬ÊÒÆ¬ÄˤÎËýÀ²½ÌäÂê¤Ë¸þ¤«¤Ã¤Æ¤¤¤¿Åö»þ¤ÎƬÄ˸¦µæ¤Î¾õ¶·¤Ë¸Æ±þ¤¹¤ë¤â¤Î¤Ç¤¢¤ë¡£¤½¤Î¸å¡¤ËýÀÊÒÆ¬ÄË¡¤ÌôʪÍðÍÑÆ¬Äˤο¤¯¤Î¸¦µæ¤¬ÏÀʸ¤È¤·¤ÆÈ¯É½¤µ¤ì¡¤¤½¤ÎÀ®²Ì¤«¤é¡¤2006ǯ¤ËËýÀÊÒÆ¬ÄË¡¤ÌôʪÍðÍÑÆ¬ÄˤÎÉÕÏ¿¿ÇÃÇ´ð½à¤¬¸ø³«¤µ¤ì¡¤ICHD-3¦Â¤Î¿ÇÃÇ´ð½à¤Ë¤Ä¤Ê¤¬¤Ã¤Æ¤¤¤ë¡£ICHD-2¤Î¤â¤¦1¤Ä¤ÎÂ礤ÊÊѹ¹ÅÀ¤Ï»°ºµ¿À·Ð¡¦¼«Î§¿À·ÐÀƬÄˤγµÇ°¤¬Æ³Æþ¤µ¤ì¤¿¤³¤È¤Ç¤¢¤ë¡£·²È¯Æ¬Äˤª¤è¤Ó·²È¯Æ¬ÄËÎà±ï¤Î°ì¼¡ÀƬÄˤμÀ´µ³µÇ°¤ÎÀ°Íý¤¬¤Ê¤µ¤ì¤Æ¤¤¤ë¡£¤Þ¤¿¡¤Àº¿À¼À´µ¤Ë¤è¤ëƬÄˤξϤ¬Àߤ±¤é¤ì¤¿¤³¤È¤âÂ礤ÊÊѹ¹ÅÀ¤Ç¤¢¤Ã¤¿¡£ ¡¡2018ǯ¤Ë¸ø³«¤µ¤ì¤¿ICHD-3¤ÏICHD-3¦Â¸ø³«¸å¤ÎÃθ«¤ä¸¦µæÊó¹ð¤Ë´ð¤Å¤¤¤Æ¿ÇÃÇ´ð½à¤Î¸«Ä¾¤·¤äÄ´À°¤¬¤Ê¤µ¤ì¤Æ¤¤¤ë¤¬¡¤Á´ÂÎŪ¤Ë¤Ï¤½¤ì¤Û¤ÉÂ礤ÊÊѹ¹¤Ï¤Ê¤µ¤ì¤Æ¤¤¤Ê¤¤¡£ ¡¡Æ¬Ä˸¦µæ¤Î¤¿¤á¤ÎƬÄË¿ÇÃǤΤߤʤ餺¡¤Æü¾ï¿ÇÎŤˤª¤±¤ëƬÄË¿ÇÃǤ⡤¹ñºÝƬÄËʬÎà¤Î¿ÇÃÇ´ð½à¤òÍѤ¤¤Æ¤Ê¤µ¤ì¤Ê¤±¤ì¤Ð¤Ê¤é¤Ê¤¤¡£¤·¤«¤·¡¤¤³¤ì¤Ï¡¤Æ¬Ä˸¦µæ¤äÆü¾ï¿ÇÎŤò¹´Â«¤¹¤ë¤â¤Î¤Ç¤Ï¤Ê¤¤¡£Ì¤²ò·è¤Î²ÝÂê¤Ë¸þ¤«¤¦¤¿¤á¤Ë¹ñºÝƬÄËʬÎà¤Î¿ÇÃÇ´ð½à¤È¤Ï°Û¤Ê¤ë¡¤¿·¤¿¤ÊƬÄËÀ¼À´µ¤ä¥µ¥Ö¥¿¥¤¥×¡¤¥µ¥Ö¥Õ¥©¡¼¥à¤òÄ󾧤¹¤ë¤³¤È¤Ï¼«Í³¤Ç¤¢¤ë¡£¤¿¤À¤·¡¤¥¹¥¿¡¼¥È¥é¥¤¥ó¤È¤·¤Æ¡¤¹ñºÝƬÄËʬÎà¤Î³µÇ°¡¤¤¹¤Ê¤ï¤Á¡¤¸½ºß¤Î¥¹¥¿¥ó¥À¡¼¥É¤òÀµ¤·¤¯Íý²ò¤·¤¿¤¦¤¨¤Ç¡¤¸¦µæ¤ò¿ÊŸ¤µ¤»¤ë¤Ù¤¤Ç¤¢¤ë¤È¤¤¤¦¤³¤È¤Ç¤¢¤ë¡£¤½¤Î¾Úº¸¤È¤·¤Æ¡¤¹ñºÝƬÄËʬÎà¤Ï½éÈǤ«¤é¡¤Â¿¤¯¤Î¸¦µæÀ®²Ì¤ò¼õ¤±¤Æ²þÄû¤µ¤ì¤Æ¤¤¤ë¤·¡¤¤Þ¤¿¡¤¥¨¥Ó¥Ç¥ó¥¹¤¬ÉÔ½½Ê¬¤Ç¤¢¤ë¤¬¡¤Í˾¤Ê³µÇ°¤ÏÉÕÏ¿¿ÇÃÇ´ð½à¤È¤·¤Æ·ÇºÜ¤µ¤ì¤Æ¤¤¤ë¤Î¤Ç¤¢¤ë¡£ ¹ñºÝƬÄËʬÎàÂè2ÈÇ¡¤Âè3ÈÇbetaÈǤ«¤éÂè3ÈǤؤμçÍפÊÊѹ¹ÅÀ ◉ÊÒÆ¬ÄË ¡¡Á°Ãû¤Î¤Ê¤¤ÊÒÆ¬ÄˤοÇÃÇ´ð½à¤Ï½éÈǰÊÍ衤Ʊ¤¸´ð½à¤¬Æ§½±¤µ¤ì¤Æ¤¤¤ë¡£¿ÇÃÇ´ð½à¤ËÊÒÆ¬Äˤλý³»þ´Ö¤Ï4¡Á72»þ´Ö¤ÈµºÜ¤µ¤ì¤Æ¤ª¤ê¡¤ICHD-2¤Ç¤ÏÃí¼á¤Ç¾®»ù¤Î¾ì¹ç¤Ïû¤¤Îã¤â¤¢¤ê1¡Á72»þ´Ö¤È¤·¤Æ¤â¤è¤¤¤«¤â¤·¤ì¤Ê¤¤¤ÈµºÜ¤µ¤ì¤Æ¤¤¤¿¡£ICHD-3¦Â¡¿3¤Ç¤Ï¡¤¾®»ù¤¢¤ë¤¤¤Ï»×½Õ´ü¤Î´µ¼Ô¤Ç¤Ï2¡Á72»þ´Ö¤È¤·¤Æ¤â¤è¤¤¤«¤â¤·¤ì¤Ê¤¤¤È¤ÎµºÜ¤ËÊѹ¹¤µ¤ì¤Æ¤¤¤ë¡£Á°Ãû¤Î¤¢¤ëÊÒÆ¬ÄˤοÇÃÇ´ð½à¤âÂ礤ÊÊѹ¹¤Ï¤Ê¤¤¡£1.2.6¡ÖǾÄì·¿ÊÒÆ¬ÄË¡ÊBasilar-type migraine¡Ë¡×¡ÊICHD-2¡Ë¤È¤µ¤ì¤Æ¤¤¤¿¤â¤Î¤¬¡¤1.2.2¡ÖǾ´´ÀÁ°Ãû¤òȼ¤¦ÊÒÆ¬ÄË¡ÊMigraine with brainstem aura¡Ë¡×¤ËÊѹ¹¤µ¤ì¤¿¡£¤Þ¤¿¡¤1.2.4¡ÖÌÖËìÊÒÆ¬ÄË¡ÊRetinal migraine¡Ë¡×¤¬¡¤Á°Ãû¤òȼ¤¦ÊÒÆ¬ÄˤΥµ¥Ö¥¿¥¤¥×¤ËÁÈ¤ßÆþ¤ì¤é¤ì¤¿¡£ ¡¡ICHD-3¦Â¤«¤éICHD-3¤Ø¤ÎÊѹ¹ÅÀ¤È¤·¤Æ¡¤1.2¡ÖÁ°Ãû¤Î¤¢¤ëÊÒÆ¬ÄË¡ÊMigraine with aura¡Ë¡×¿ÇÃÇ´ð½à¤Ë¤ª¤¤¤Æ¡¤¹àÌÜC¤¬4¹àÌܤ«¤é6¹àÌܤËÁý²Ã¤·¤¿¤³¤È¡¤ICHD-3¦Â¤ÎÉÕÏ¿A1.2¡ÖÁ°Ãû¤Î¤¢¤ëÊÒÆ¬ÄË¡ÊMigraine with aura¡Ë¡×¿ÇÃÇ´ð½à¤¬Ëܧ¤È¤·¤Æ·ÇºÜ¤µ¤ì¤¿ÅÀ¤¬µó¤²¤é¤ì¤ë¡£ ¡¡1.3¡ÖËýÀÊÒÆ¬ÄË¡ÊChronic migraine¡Ë¡×¤¬ÊÒÆ¬ÄˤιçÊ»¾É¤Î¥µ¥Ö¥Õ¥©¡¼¥à¤«¤é¡¤ÊÒÆ¬ÄˤΥµ¥Ö¥¿¥¤¥×¤Ë·ÇºÜ¤µ¤ì¡¤Á°Ãû¤Î¤Ê¤¤ÊÒÆ¬ÄË¡¤Á°Ãû¤Î¤¢¤ëÊÒÆ¬ÄË¤ÈÆ±¥ì¥Ù¥ë¤ÎƬÄË¥«¥Æ¥´¥ê¡¼¤È¤·¤Æ°·¤ï¤ì¤Æ¤¤¤ë¡£Ä̾ȿÉüÀ¤ÎÊÒÆ¬ÄˤÎȯºîÉÑÅÙ¤¬Áý²Ã¤·¡¤ËýÀÊÒÆ¬Äˤ˿ÊŸ¤¹¤ë¤Î¤ÇÊÒÆ¬ÄˤιçÊ»¾É¤È°ÌÃ֤Ť±¤é¤ì¤Æ¤¤¤¿¤¬¡¤¶ÛÄ¥·¿Æ¬Äˤ䡤·²È¯Æ¬Äˤˤª¤±¤ëÈ¿ÉüÀ¡¤ËýÀ¤Î³µÇ°¤ÈÅý°ì¤¹¤ë¤È¤¤¤¦´ÑÅÀ¤«¤é½¤Àµ¤¬¤Ê¤µ¤ì¤Æ¤¤¤ë¡£ ¡¡1.3¡Ö¾®»ù¼þ´üÀ¾É¸õ·²¡ÊÊÒÆ¬Äˤ˰ܹԤ¹¤ë¤³¤È¤¬Â¿¤¤¤â¤Î¡Ë¡ÊChildhood periodic syndromes that are commonly precursors of migraine¡Ë¡×¡ÊICHD-2¡Ë¤Ï1.6¡ÖÊÒÆ¬Äˤ˴ØÏ¢¤¹¤ë¼þ´üÀ¾É¸õ·²¡ÊEpisodic syndromes that may be associated with migraine¡Ë¡×¤ËÊѹ¹¤µ¤ì¤¿¡£1.6.1.1¡Ö¼þ´üÀÓÒÅǾɸõ·²¡ÊCyclical vomiting syndrome¡Ë¡×¤Ê¤É¤Ï¾®»ù¤Ë¿¤¤¤¬À®¿ÍÎã¤â¤¢¤ë¤³¤È¤«¤é¡Ö¾®»ù¡×¤¬ºï½ü¤µ¤ì¤Æ¤¤¤ë¡£1.6.3¡ÖÎÉÀȯºîÀ¼Ððô¡ÊBenign paroxysmal torticollis¡Ë¡×¤Ï¤³¤³¤Ë·ÇºÜ¤µ¤ì¤Æ¤¤¤ë¡ÊICHD-2¤Ç¤ÏÉÕÏ¿¤Ë·ÇºÜ¤µ¤ì¤Æ¤¤¤¿¡Ë¡£ ¡¡ÊÒÆ¬ÄˤȤá¤Þ¤¤¤Î´ØÏ¢¤¬ÃíÌܤµ¤ì¤Æ¤¤¤¿¡£Æ¬ÄËÀ¼À´µ¤Î¼À´µÃ±°Ì¤È¤·¤Æ¤Î°ÕµÁ¤Ë¤Ä¤¤¤Æ¤¤¤¯¤Ä¤«¤ÎµÄÏÀ¤ò·Ð¤Æ¡¤ÉÕÏ¿¤ËA1.6.6¡ÖÁ°ÄíÀÊÒÆ¬ÄË¡ÊVestibular migraine¡Ë¡×¤¬·ÇºÜ¤µ¤ì¤¿¡£º£¸å¤Î¾ÉÎã¤ÎÃßÀѤȸ¡Æ¤¤¬´üÂÔ¤µ¤ì¤Æ¤¤¤ë¡£ ◉¶ÛÄ¥·¿Æ¬ÄË ¡¡¶ÛÄ¥·¿Æ¬ÄˤˤÏÂ礤ÊÊѹ¹¤Ï¤Ê¤¤¡£ ◉»°ºµ¿À·Ð¡¦¼«Î§¿À·ÐÀƬÄË¡ÊTACs¡Ë ¡¡ICHD-2¤Ç¤Ï¡¤Âè3¾Ï¤Ï¡Ö·²È¯Æ¬Äˤª¤è¤Ó¤½¤Î¾¤Î»°ºµ¿À·Ð¡¦¼«Î§¿À·ÐÀƬÄˡפȵºÜ¤µ¤ì¤Æ¤¤¤¿¡£ICHD-3¦Â¡¿3¤Ç¤Ï¡¤TACs¤Î³µÇ°¤ÎÉáµÚ¤ò¼õ¤±¤Æ¡¤Âè3¾Ï¤ÎƬÄË¥°¥ë¡¼¥×̾¤«¤é·²È¯Æ¬Äˤ¬¾Ã¤¨¡¤¡Ö»°ºµ¿À·Ð¡¦¼«Î§¿À·ÐÀƬÄË¡ÊTACs¡Ë¡×¤È¤Ê¤Ã¤Æ¤¤¤ë¡£ ¡¡3.3¡Öû»þ´Ö»ý³ÀÊÒ¦¿À·ÐÄËÍÍÆ¬ÄËȯºî¡ÊShort-lasting unilateral neuralgiform headache attacks¡Ë¡×¤¬·ÇºÜ¤µ¤ì¡¤¤³¤Î¥µ¥Ö¥Õ¥©¡¼¥à¤ËSUNCT¤ÈSUNA¤¬µºÜ¤µ¤ì¤¿¡£ICHD-2¤Ç¤ÏSUNCT¤ÏÂè3¾Ï¤Ë¡¤SUNA¤ÏÉÕÏ¿¤Ë·ÇºÜ¤µ¤ì¤Æ¤¤¤¿¡£ICHD-3¦Â¡¿3¤Ç¤Ï¤³¤ì¤é¤¬Åý¹ç¤µ¤ì¤Æ·ÇºÜ¤µ¤ì¤Æ¤¤¤ë¡£ ¡¡3.4¡Ö»ý³ÀÊÒ¦ƬÄˡפ¬¡¤¡Ö¤½¤Î¾¤Î°ì¼¡ÀƬÄˡפ«¤é¡¤¡Ö»°ºµ¿À·Ð¡¦¼«Î§¿À·ÐÀƬÄË¡ÊTACs¡Ë¡×¤Ë°Ü¤µ¤ì¤¿¡£ICHD-3¦Â¤«¤éICHD-3¤Ø¤ÎÊѹ¹¤Ç¤Ï¡¤3.1¡Ö·²È¯Æ¬Äˡס¤3.2¡ÖȯºîÀÊÒ¦ƬÄˡס¤3.3¡Öû»þ´Ö»ý³ÀÊÒ¦¿À·ÐÄËÍÍÆ¬ÄËȯºî¡×¡¤3.4¡Ö»ý³ÀÊÒ¦ƬÄˡפ˴ؤ¹¤ë¿ÇÃÇ´ð½àC¹àÌܤËICHD-3¦Â¤ÇÄɲ䵤줿¡¤¡ÖÁ°³ÛÉô¤ª¤è¤Ó´éÌ̤ιÈĬ¡×¤È¡Ö¼ªÊÄ´¶¡×¤¬¡¤ICHD-3¤Ç¤Ïºï½ü¤µ¤ì¤Æ¤¤¤ë¤³¤È¡¤3.1.2¡ÖËýÀ·²È¯Æ¬ÄˡפοÇÃÇ´ð½àB¹àÌܤˤª¤¤¤Æ¡¤´²²ò´ü¤Î´ü´Ö¤¬¡Ö1¥õ·î̤Ëþ¡×¤«¤é¡Ö3¥õ·î̤Ëþ¡×¤ËÊѹ¹¤µ¤ì¤¿¤³¤È¤Ê¤É¤¬µó¤²¤é¤ì¤ë¡£ ◉¤½¤Î¾¤Î°ì¼¡ÀƬÄ˼À´µ ¡¡ICHD-3¦Â¡¿3¤Ç¤Ï4.5¡Ö´¨Îä»É·ã¤Ë¤è¤ëƬÄË¡ÊCold-stimulus headache¡Ë¡×¡¤4.6¡ÖƬ³¸³°¤«¤é¤Î°µÎϤˤè¤ëƬÄË¡ÊExternal-pressure headache¡Ë¡×¤¬Âè13¾Ï¤«¤éÂè4¾Ï¤Ë°Ü¤µ¤ì¡¤4.8¡Ö²ßʾ¾õƬÄË¡ÊNummular headache¡Ë¡×¤¬ÉÕÏ¿¿ÇÃÇ´ð½à¤«¤éËܾϤËÁȤ߹þ¤Þ¤ì¤Æ¤¤¤ë¡£4.10¡Ö¿·µ¬È¯¾É»ý³ÀÏ¢ÆüÀƬÄË¡ÊNew daily persistent headache¡§NDPH¡Ë¡×¤Î¿ÇÃÇ´ð½à¤«¤éƬÄˤÎÀ¾õ¤¬ºï½ü¤µ¤ì¡¤ÊÒÆ¬ÄËÍÍ¤ÎÆ¬ÄˤǤ¢¤Ã¤Æ¤â¿·µ¬¤Ëȯ¾É¤¹¤ì¤Ð´Þ¤á¤ë¤è¤¦¤ËÊѹ¹¤µ¤ì¤¿¡£ ◉Æó¼¡ÀƬÄË ¡¡Æó¼¡ÀƬÄˤΰìÈÌ¿ÇÃÇ´ð½à¤Ï¡¤¸¶°ø¤È¤Ê¤ë¼À´µ¤Î²þÁ±¤ä¾Ã¼º¤Ë¤è¤ëƬÄˤβþÁ±¤ÎÍ×·ï¤òºï½ü¤·¤¿¤³¤È¤¬Âç¤¤ÊÆÃħ¤Ç¤¢¤ë¡£ÌôʪÍðÍÑÆ¬ÄˤòÎã¤Ë¤È¤ì¤Ð¡¤ICHD-2¤Ç¤Ï¸¶°øÌôºÞ¤ÎÃæ»ß¤Ë¤è¤ëƬÄˤηڸº¤¬¿ÇÃÇÍ×·ï¤Ç¤¢¤Ã¤¿¤¬¡¤ICHD-3¦Â¡¿3¤Ç¤Ï¸¶°øÌôºÞ¤òÃæ»ß¤¹¤ëÁ°¤Ç¤â¤½¤Î°ø²Ì´Ø·¸¤ò¼¨¤¹¾Úµò¤¬¤¢¤ì¤Ð¿ÇÃǤ¬¤Ç¤¤ë¤è¤¦¤ËÊѹ¹¤µ¤ì¤¿¡£ ¡¡ICHD-3¦Â¤«¤éICHD-3¤Ø¤ÎÊѹ¹ÅÀ¤Î¾ÜºÙ¤Ë¤Ä¤¤¤Æ¤Ï¡¤Á°½Ò¤ÎÄ̤êÆüËÜÆ¬Ä˳زñ¤Îweb site¤Ë¡Ö¹ñºÝƬÄËʬÎàÂè3ÈǸø³«¤Î¤´°ÆÆâ¡×¤È¤È¤â¤Ë·ÇºÜ¤µ¤ì¤Æ¤¤¤ë¡£ ËÝÌõ¤Î´ðËÜÊý¿Ë¤ÈÍѸìÊѹ¹ ¡¡ËÝÌõ¤Î´ðËÜÊý¿Ë¤ÏÂè2ÈǤÎËÝÌõ¤ÎÊý¿Ë¤ò°ú¤·Ñ¤¤¤Ç¤¤¤ë¡£¿ÇÃÇ´ð½à¤ÏľÌõ¤·¡¤Â¿¾¯ÆüËܸì¤È¤·¤ÆÉÔ¼«Á³¤Ç¤â¸¶Ê¸¤ËÃé¼Â¤Ç¤¢¤ë¤³¤È¤ò½Å»ë¤·¤¿¡£¿ÇÃÇ´ð½à¤ò¸¦µæÌÜŪ¤Ç»ÈÍѤ¹¤ëºÝ¤Ë¤Ï¡¤É¬¤º¸¶Ê¸¤â³Îǧ¤·¤Æ²ò¼á¤·¤Æ¤¤¤¿¤À¤¤¿¤¤¡£²òÀ⡤¥³¥á¥ó¥ÈÉôʬ¤ÏÆÉ¼Ô¤ÎÆÉ¤ß¤ä¤¹¤µ¡¤Íý²ò¤·¤ä¤¹¤µ¤ò½Å»ë¤·¡¤Â¿¾¯¤Î°ÕÌõ¤òµöÍÆ¤·¤¿¡£Á´ÂΤòÄ̤·¤ÆÍѸì¤Ï¤Ê¤ë¤Ù¤¯Åý°ì¤¹¤ë¤è¤¦¤Ë¤·¤¿¤¬¡¤¸¶Ê¸¤Ë¤¢¤ëÉÔÅý°ì¤Ï¸¶Â§¤½¤Î¤Þ¤Þ»Ä¤·¤ÆËÝÌõ¤·¤¿¡£¤¿¤À¤·¡¤ÌÀ¤é¤«¤Ê¥ß¥¹¥×¥ê¥ó¥È¤äæÍî¤Ï¡¤¸¶ËܤγºÅö¾Ï¤ÎÀÕǤ¼Ô¤Ë¥á¡¼¥ëÅù¤ÇÏ¢Íí¤ò¤È¤ê¡¤³Îǧ¤Î¾å¡¤½¤Àµ¤·¤ÆËÝÌõ¤·¤¿¡£Æ±¤¸±Ññ¸ì¤Ç¤âʸ̮¤Ë¤è¤êÌõ¸ì¤¬°Û¤Ê¤ë¾ì¹ç¤¬¤¢¤ê¡¤¤Þ¤¿°Û¤Ê¤ë±Ññ¸ì¤¬Æ±¤¸ÆüËܸìÌõ¤Ë¤Ê¤ë¤³¤È¤â¤¢¤ë¡£ Ìõ¤Ë¤Ä¤¤¤Æ¤Î¥³¥á¥ó¥È¡ÊËÝÌõ¥Î¡¼¥È¡Ë ◉ICHD-II¡¿ICHD-2¡¤ICHD-III¡¿ICHD-3 ¡¡Âè3ÈÇ¤Ç¤Ï¥í¡¼¥Þ¿ô»ú¤Ç¤Ï¤Ê¤¯»»ÍÑ¿ô»ú¤Î3¤ò»ÈÍѤ¹¤ë¤³¤È¤ò¸¶Â§¤È¤·¤¿¡£¤³¤ì¤Ë¹ç¤ï¤»¤Æ¡¤ICHD-II¤â¸¶Â§»»ÍÑ¿ô»ú¤òÍѤ¤¤ÆICHD-2¤Îɽµ¤òÍ¥À褹¤ë¡£ ◉headache disorder ¡¡¡ÖƬÄËÀ¼À´µ¡×¤ÎÌõ¸ì¤òºÎÂò¤·¤¿¡£¡Èprimary headache¡É¤ÏICHD-2¤òƧ½±¤·¡Ö°ì¼¡ÀƬÄˡפȤ·¤¿¡£¡Èprimary headache disorder¡É¤Ï¡¤¡Ö°ì¼¡ÀƬÄËÀ¼À´µ¡×¤È¤¹¤ë¤È¾éŤǤ¢¤ë¤¿¤á¡ÈÀ¡É¤ò¤Ò¤È¤Ä¾Êά¤·¤Æ¡Ö°ì¼¡ÀƬÄ˼À´µ¡×¤È¤·¤¿¡£ ◉evidence ¡¡¡Ö¾Úµò¡×¡Ö³Î¾Ú¡×¡Öº¬µò¡×¡Ö¥¨¥Ó¥Ç¥ó¥¹¡×¤Ê¤É¤ÎÌõ¸ì¤¬³ºÅö¤¹¤ë¤¬¡¤¸¶Â§¤È¤·¤Æ¡Ö¾Úµò¡×¤ÈËÝÌõ¤·¡¤Ê¸Ì®¤Ë¤è¤ê¾¤ÎÌõ¸ì¤¬Å¬Àڤʾì¹ç¤ÏÎ㳰Ū¤Ë¾¤ÎÌõ¸ì¤òºÎÍѤ·¤¿¡£ ◉ƬÄËÉÂ̾¡¤¥³¡¼¥É¤Î¸Æ¾Î ¡¡ICHD-3¦Â¡¿3¤Î¸¶Ê¸¤Ë¤ª¤¤¤Æ¡¤´¬Æ¬Ìܼ¡¡¤³Æ¾Ï¤ÎÌܼ¡¡¤ËÜÊ¸Ãæ¤Î¹àÌܸ«½Ð¤·¤È¤·¤Æ¤ÎƬÄËÉÂ̾¤ËºÙÉô¤ÇÉÔ°ìÃפ¬»Ä¤Ã¤Æ¤¤¤ë¡£¸¶Â§¤È¤·¤Æ¡¤ËÜÊ¸Ãæ¤Î¹àÌܸ«½Ð¤·¤Ë»ÈÍѤµ¤ì¤¿Æ¬ÄË̾¾Î¤òÀµ¼°Ì¾¾Î¤È¤·¤Æ°·¤¤ËÝÌõ¤·¤¿¡£ ¡¡¹ñºÝƬÄËʬÎà¤Ç¤ÏƬÄËÉÂ̾¤ò³¬Áع½Â¤¤Ç¥³¡¼¥É²½¤·¤Æ¤¤¤ë¡£ICHD-3¦Â¤Þ¤Ç¤Ï1·å¤Î¥³¡¼¥É¤Ï¥°¥ë¡¼¥×¤ª¤è¤Ó¥¿¥¤¥×¤ò¼¨¤·¡¤2·å¤Ï¥µ¥Ö¥¿¥¤¥×¡¤3·å°Ê¾å¤Î¥³¡¼¥É¤Ï¥µ¥Ö¥Õ¥©¡¼¥à¤È¤·¤Æ°·¤ï¤ì¤Æ¤¤¤¿¤¬¡¤¾Ï¤Ë¤è¤êɬ¤º¤·¤âÅý°ì¤µ¤ì¤Æ¤¤¤Ê¤«¤Ã¤¿¡£ICHD-3¤Ç¤Ï2·å¤ò¥¿¥¤¥×¡¤3·å¤ò¥µ¥Ö¥¿¥¤¥×¡¤4·å°Ê¾å¤ò¥µ¥Ö¥Õ¥©¡¼¥à¤È¤·¤Æ°·¤¦¤³¤È¤¬ÌÀµ¤µ¤ì¤¿¡£ ◉classical ¡¡Ä̾¡Èclassic¡É¤Ï¡Öŵ·¿Åª¡×¡¤¡Èclassical¡É¤Ï¡Ö¸ÅŵۡפÈÌõ¤µ¤ì°Û¤Ê¤ë°ÕÌ£¤È¤µ¤ì¤ë¤³¤È¤â¤¢¤ë¤¬¡¤ICHD-3¤Ç¤Ï¡Èclassical¡É¤¬¡Öŵ·¿Åª¡×¤Î°ÕÌ£¤ÇÍѤ¤¤é¤ì¤Æ¤ª¤ê¡Öŵ·¿Åª¡×¤òºÎÂò¤·¤¿¡£IHS¤ÎôÅö°Ñ°÷¤Ë¡¤¡Ö¸ÅŵŪ¡×¤È¤¤¤¦¥Ë¥å¥¢¥ó¥¹¤¬¤Ê¤¤¤³¤È¤ò³Îǧ¤·¤Æ¤¤¤ë¡£ ◉premonitory symptoms¡¤prodrome¡ÊͽÃû¡¿Á°¶î¾É¾õ¡Ë¡¤postdromal symptom¡¤postdrome¡Ê¸åȯ¾É¾õ¡Ë ¡¡ÊÒÆ¬ÄˤΡÖÁ°Ãû¡Êaura¡Ë¡×¤Ï°ì²áÀ¤Î¶ÉºßǾµ¡Ç½¾ã³²¤Ç¡¤Á®µ±°ÅÅÀ¤ä´¶³Ð¾ã³²¤Ê¤É¤ò¤µ¤¹¡£°ìÊý¡¤ÊÒÆ¬ÄËȯºî¤ÎÁ°¤Ëµ¯¤³¤ëµ¤Ê¬¤ÎÊÑÄ´¤ä¿©ÍߤÎÊѲ½¤Ê¤ÉÇùÁ³¤È¤·¤¿¾É¾õ¤Ï¡Èpremonitory symptoms¡É¤Èɽ¸½¤µ¤ì¤ë¡£¡Èprodrome¡É¤Ï¤¢¤¤¤Þ¤¤¤ÊÍѸì¤Ç¡¤¡Èaura¡É¤ò´Þ¤á¤ÆÍѤ¤¤é¤ì¤ë¤³¤È¤â¤¢¤ê¡¤Èò¤±¤ë¤Ù¤ÍѸì¤È¤µ¤ì¤Æ¤¤¿¡£¡Èpremonitory symptoms, prodrome¡É¤ÎÌõ¸ì¤È¤·¤Æ¡ÖͽÃû¡×¡ÖÁ°¶î¾É¾õ¡×¤Ê¤É¤¬ÍѤ¤¤é¤ì¤Æ¤ª¤ê¡¤Ê¸¸¥¤Ë¤è¤ê¤µ¤Þ¤¶¤Þ¤Ç¤¢¤ë¡£Âè2ÈÇÆüËܸìÈǤǤϡÈpremonitory symptoms¡É¤Ë¡ÖÁ°¶î¾É¾õ¡×¡¤¡Èprodrome¡É¤Ë¤Ï¡ÖͽÃû¡×¤ÎÌõ¸ì¤ò¤¢¤Æ¤¿¤¬¡¤Âè3ÈÇbetaÈÇ¡¤Âè3ÈǤǤÏξÊý¤ÎÌõ¸ì¤òÊ»µ¤·¤¿¡£¸·Ì©¤Ê°ÕÌ£¤Ç¤Î¡Èpremonitory symptoms¡É¤ò»Ø¤¹¾ì¹ç¤Ë¤ÏÆüËܸì¤Ç¤Ï¡ÖͽÃû¡×¤ò»ÈÍѤ¹¤ë¤è¤¦Ä󾧤ò¤·¤Æ¤¤¿¡£ICHD-3¤Ç¤Ï¹ñºÝƬÄËʬÎà°Ñ°÷²ñ¤ÎÊý¿Ë¤ÎÊѹ¹¤¬¤¢¤ê¡¤Æ¬ÄËȯºî¤ËÁ°¤Î¾É¾õ¤Ë¡Èprodrome¡É¤¬¤¢¤Æ¤é¤ì¤Æ¤¤¤ë¡£¤µ¤é¤Ë¡¤Æ¬ÄË´ü¤Î¸å¤Î¤µ¤Þ¤¶¤Þ¤Ê¾É¾õ¤¬¡¤¡Èpostdromal symptom¡Êpostdrome¡Ë¡É¤È¤·¤ÆµºÜ¤µ¤ì¤Æ¤¤¤ë¡£»ÈÍѤ¹¤ëÍѸì¤È¿ä¾©¤ÎÊѹ¹¤ÎÍýͳ¤Ë¤Ä¤¤¤Æ¡¤¹ñºÝƬÄËʬÎà°Ñ°÷²ñ¤Ë¾È²ñ¤·¤¿¤È¤³¤í¡¤Olesen°Ñ°÷Ĺ¤Ê¤é¤Ó¤ËôÅö°Ñ°÷¤«¤é²óÅú¤òÆÀ¤¿¡£ICHD-3¤Ç»ÈÍѤ¹¤ë¡Èprodrome¡É¤Ï¤³¤ì¤Þ¤Ç¤Î¡Èpremonitory symptoms¡É¤ÈƱµÁ¤Ç¤¢¤ë¡£ÊÒÆ¬ÄˤÎÉÂÂ֤Ȥ·¤ÆÆ¬Äˤ¬µ¯¤³¤ëÁ°¤«¤é¿À·Ð·Ï¤Ë¤ª¤±¤ëÊѲ½¤¬»Ï¤Þ¤Ã¤Æ¤ª¤ê¤³¤ÎºÝ¤Î¾É¾õ¤¬¡Èprodrome¡É¤Ç¤¢¤ê¡¤Æ¬ÄË´ü¤Î¸å¤Ë°ìÏ¢¤Î¿À·Ð·Ï¤Î°Û¾ï¤¬Â³¤¯¤¬¤³¤ì¤ò¡Èpostdrome¡É¤È¤·¤¿¡£¤³¤Îή¤ì¤ò¤è¤ê¤è¤¯Íý²ò¤·ÂоÎÀ¤ËÇÛθ¤·¤Æ¡¤¤³¤ÎÊѹ¹¤¬·èÄꤵ¤ì¤¿¤È¤Î¤³¤È¤Ç¤¢¤Ã¤¿¡£¤Þ¤¿¡¤ÆüËܸìÈǤκîÀ®¤Ë¤¢¤¿¤Ã¤Æ¡¤¡Èprodrome¡É¤È¡Èpostdrome¡É¤ÏÊÒÆ¬ÄËȯºî¤Î°ìÏ¢¤Î¸½¾Ý¤Î°ìÉô¤Ç¤¢¤ê¡¤Æ¬ÄËȯºî¤È¤ÏÊ̤˵¯¤³¤ë¸½¾Ý¤Ç¤Ï¤Ê¤¤¤³¤È¤ò¶¯Ä´¤·¤Æ¤Û¤·¤¤¤È¤Î¼¨º¶¤ò¼õ¤±¤¿¡£¤³¤ì¤é¤ò´ª°Æ¤·¡¤¡Èpostdrome¡É¤Ë¤Ï¸åȯ¾É¾õ¤ÎÌõ¸ì¤ò¤¢¤Æ¤¿¡£Æ¬ÄËȯºîÁ°¤Î¾É¾õ¤Ë¤Ä¤¤¤Æ¤Ï¡¤Ìõ¸ì¤Ï¡¤Í½Ãû¡Êprodrome¡Ë¤ÈÁ°Ãû¡Êaura¡Ë¤ò»ÈÍѤ¹¤ë¤³¤È¤È¤·¤¿¡£ ◉1.2.2¡ÖǾ´´ÀÁ°Ãû¤òȼ¤¦ÊÒÆ¬ÄˡפÎÃí④ ¡¡1.2.2¡ÖǾ´´ÀÁ°Ãû¤òȼ¤¦ÊÒÆ¬ÄˡפÎÃí④¤Ï¸¶Ê¸¤Ç¤Ï¡ÈDiplopia does not embrace¡Êor exclude¡Ëblurred vision¡É¤ÈµºÜ¤µ¤ì¤Æ¤¤¤ë¡£¿ÇÃÇ´ð½à¤ÎËÝÌõ¤Î¸¶Â§¤Ë±è¤Ã¤ÆÄ¾Ìõ¤¹¤ë¤È¡ÖÊ£»ë¤Ï̸»ë¤ò´Þ¤Þ¤Ê¤¤¡×¤È¤¹¤Ù¤¤«¤â¤·¤ì¤Ê¤¤¤¬¡¤°ÕÌ£¤¬Û£Ëæ¤Ë¤Ê¤ê¤¹¤®¤ë¤Î¤Ç¡Ö̸»ë¤Î¤ß¤Ç¤ÏÊ£»ë¤È¤·¤Ê¤¤¡×¤È°ÕÌõŪ¤ÊËÝÌõ¤òºÎÂò¤·¤¿¡£ ◉Ê£¿ô¤ÎƬÄË¿ÇÃÇ̾¤ÎµºÜ½ç¤Î¥ë¡¼¥ë ¡¡2.4¡Ö¶ÛÄ¥·¿Æ¬Äˤε¿¤¤¡ÊProbable tension-type headache¡Ë¡×¤Î¥³¥á¥ó¥È¤Ë¡Ö¤³¤Î¤è¤¦¤Ê¾ÉÎã¤Ç¤Ï¡¤¥³¡¼¥ÉÈÖ¹æ½ç¤Ë¤¹¤ëµ¬Â§¤Ë½¾¤¤¡¤¡Ä¡×¤ÈµºÜ¤µ¤ì¤Æ¤¤¤ë¡Ê25Êǡˡ£°ìÊý¡¤¡Ö¤³¤ÎʬÎà¤Î»È¤¤Êý¡×¤Î4ÈÖ¡ÊÁ°ÉÕ31Êǡˤˤϡ֤½¤Î´µ¼Ô¤Ë¤È¤Ã¤Æ½ÅÍפʽç¤ËµºÜ¤¹¤Ù¤¤Ç¤¢¤ë¡×¤ÈµºÜ¤µ¤ì¤Æ¤¤¤ë¡£ÊÒÆ¬Äˤε¿¤¤¤È¶ÛÄ¥·¿Æ¬Äˤε¿¤¤¤Îξ¿ÇÃǤ¬É¬Íפʾì¹ç¤Ç¡¤½ÅÍ×À¤¬Æ±ÄøÅ٤Ǥ¢¤ì¤Ð¥³¡¼¥ÉÈÖ¹æ½ç¤ËµºÜ¤¹¤ë¤ÈÍý²ò¤Ç¤¤ë¡£ ◉¥¤¥ó¥É¥á¥¿¥·¥ó¤ÎÍÑÎÌ ¡¡3.2¡ÖȯºîÀÊÒ¦ƬÄË¡ÊProxysmal hemicrania¡Ë¡×¡¤3.4¡Ö»ý³ÀÊÒ¦ƬÄË¡ÊHemicrania continua¡Ë¡×¤Î¿ÇÃÇ´ð½à¤ÎÃí¤Ë¤Ï¡ÖÀ®¿Í¤Ç¤Ï·Ð¸ý¥¤¥ó¥É¥á¥¿¥·¥ó¤ÏºÇÄãÍÑÎÌ150 mg¡¿Æü¤ò½é´üÅêÍ¿¤È¤·¤Æ»ÈÍѤ·¡¤É¬Íפ¬¤¢¤ì¤Ð225 mg¡¿Æü¤ò¾å¸Â¤ËÁýÎ̤¹¤ë¡×¤Èµ½Ò¤µ¤ì¤Æ¤¤¤ë¡£¤ï¤¬¹ñ¤Ç¤Ï¡¤¥¤¥ó¥É¥á¥¿¥·¥ó·Ð¸ýÌô¤Î»ÈÍÑÎ̤ϺǹâÎÌ75 mg¡¿Æü¤Þ¤Ç¡¤Ä¾Ä²ÅêÍ¿¡ÊºÁÌô¡Ë¤ÏºÇ¹âÎÌ100 mg¡¿Æü¤Þ¤Ç¤È¤µ¤ì¤Æ¤¤¤ë¡£¤ï¤¬¹ñ¤Ç¤Ï¤³¤ì°Ê¾å¤ÎÍÑÎ̤ΰÂÁ´À¤¬³Îǧ¤µ¤ì¤Æ¤¤¤Ê¤¤¤Î¤Ç¡¤ICHD-3¤Î¿ÇÃÇ´ð½à¤ÎµºÜ¤Ë¤¢¤ëÍÑÎ̤λÈÍѤϰìÈ̤ˤϿ侩¤Ç¤¤Ê¤¤¡£Æü¾ïÎ×¾²¤Ç¤Ï75 mg¡¿Æü¤Þ¤Ç¤ÎÅêÍ¿¤ÇÈ¿±þÀ¤òȽÃǤ·¤Æ¤è¤¤¤È¹Í¤¨¤é¤ì¤ë¤¬¡¤75 mg¡¿Æü¤Î¥¤¥ó¥É¥á¥¿¥·¥ó¤¬Ìµ¸ú¤Î¾ì¹ç¤ÏÎ×¾²ÅªÆÃħ¤ä¹³¤Æ¤ó¤«¤óÌô¤È¤ÎÁê¾è¸ú²Ì¤Ê¤É¤â´ª°Æ¤·Áí¹çŪ¤ËȽÃǤ¹¤ëɬÍפ¬¤¢¤ë¡£ ◉3.3¡Öû»þ´Ö»ý³ÀÊÒ¦¿À·ÐÄËÍÍÆ¬ÄËȯºî¡×¤Îµø»õ¾õ¥Ñ¥¿¡¼¥ó¡Êsaw-tooth pattern¡Ë ¡¡Ã»»þ´Ö»ý³ÀÊÒ¦¿À·ÐÄËÍÍȯºî¤Îȯ¸½¥Ñ¥¿¡¼¥ó¤Î1¤Ä¤È¤·¤ÆICHD-3¦Â¤Ë¤ª¤¤¤Æ¡Èsaw-tooth pattern¡É¤È¤¤¤¦¸ÀÍÕ¤¬µºÜ¤µ¤ì¤Æ¤¤¤ë¡£¤½¤Î¸¶Ãø¡ÊCohen AS, et al. Brain 2006¡¨129¡§2746-2760¡Ë¤Ç¤Ï¡¤¡Ö»ÉÄˤ¬²¿²ó¤«·«¤êÊÖ¤·¼«³Ð¤µ¤ì¡¤»ÉÄˤȻÉÄˤδ֤ˤª¤¤¤Æ¤âÈæ³ÓŪ½ÅÅÙ¤ÎÄˤߤ¬°Ý»ý¤µ¤ì¡¤¥Ù¡¼¥¹¥é¥¤¥ó¤Ë¤Þ¤ÇÌá¤é¤Ê¤¤»ý³»þ´Ö¤ÎŤ¤È¯ºî¡×¤È½Ò¤Ù¤é¤ì¤Æ¤¤¤ë¡£º£²ó¡Èsaw-tooth pattern¡É¤ËÁêÅö¤¹¤ëÆüËܸì¤È¤·¤Æ¡Öµø»õ¾õ¥Ñ¥¿¡¼¥ó¡×¤òºÎÍѤ¹¤ë¤³¤È¤È¤·¤¿¡£È¯ºîȯ¸½¥Ñ¥¿¡¼¥ó¤È¤·¤Æ¤ÏñȯÀ¤Î»ÉÄË¡¦Â¿È¯À¤Î»ÉÄË¡¦µø»õ¾õ¥Ñ¥¿¡¼¥ó¤Î3¤Ä¤¬¤¢¤ê¡¤¤½¤ì¤¾¤ì¤Î»þ´Ö·Ð²á¤ò°Ê²¼¤Ë¼¨¤·¤¿¡£ ◉´²²ò´ü ¡¡ICHD-3¦Â¡¿3¤Î²òÀâ¤È¿ÇÃÇ´ð½à¤Î¸¶Ê¸¤Ç¤ÏTACs¤Î´²²ò´ü¤ò¡Èpain-free period¡É¡Èremission period¡É¤¢¤ë¤¤¤Ï¡Èpain-free remission period¡É¤Èɽ¸½¤·¤Æ¤¤¤ë¡£IHS¤ÎôÅö°Ñ°÷¤ÈÏ¢Íí¤ò¤È¤ê¡¤¤³¤Î3¤Ä¤ÎÍѸì¤ËËܼÁŪ¤Ê°ã¤¤¤¬¤Ê¤¤¤³¤È¤ò³Îǧ¤·¤¿¡£ÆüËܸìÌõ¤Ç¤Ï¤³¤ì¤é3¼Ô¤ÎÌõ¤ò¡Ö´²²ò´ü¡×¤ËÅý°ì¤·¤¿¡£ ◉4.2¡Ö°ì¼¡À±¿Æ°»þƬÄË¡ÊPrimary exercise headache¡Ë¡× ¡¡ICHD-2¤Î¡Ö°ì¼¡ÀÏ«ºîÀƬÄË¡ÊPrimary exertional headache¡Ë¡×¤Ë³ºÅö¤¹¤ë¡£¡Èexertional¡É¤«¤é¡Èexercise¡É¤ÎÊѹ¹¤òÈ¿±Ç¤·¡ÖÏ«ºî¡×¤«¤é¡Ö±¿Æ°¡×¤È¤·¤¿¡£¡Ö°ì¼¡À±¿Æ°ÀƬÄˡפȤ¹¤ë¤«¡¤¡Ö°ì¼¡À±¿Æ°»þƬÄˡפȤ¹¤ë¤«¤Ë¤Ä¤µÄÏÀ¤¬¤Ê¤µ¤ì¤¿¤¬¡¤¡Ö±¿Æ°»þƬÄˡפòºÎÂò¤·¤¿¡£ ◉4.10¡Ö¿·µ¬È¯¾É»ý³ÀÏ¢ÆüÀƬÄË¡ÊNew daily persistent headache¡Ë¡×¤Îɽµ ¡¡¡ÈNew daily persistent headache¡É¤ÎÆüËÜ¸ìÆ¬ÄËÉÂ̾¤ÏÂè2ÈǤ«¤é¡Ö¿·µ¬È¯¾É»ý³ÀÏ¢ÆüÀƬÄˡפ¬ºÎÂò¤µ¤ì¤Æ¤¤¤ë¡£Æ¬ÄËÉÂ̾¤Î¡Èdaily¡É¡ÖÏ¢ÆüÀ¡×¤È¡Èpersistent¡É¡Ö»ý³À¡×¤Î¸ì½ç¤¬±Ñʸ¤ÈÆüËܸì¤ÇÆþ¤ìÂØ¤ï¤Ã¤Æ¤¤¤ë¡£¤³¤ì¤ÏËýÀÏ¢ÆüÀƬÄˤʤɡÖÏ¢ÆüÀƬÄˡפÎɽ¸½¤¬ÄêÃ夷¤Æ¤ª¤ê¡Ö»ý³ÀƬÄˡפǤÏÍý²ò¤·¤Å¤é¤¤¤È¤Î´ÑÅÀ¤«¤éÊѹ¹¤µ¤ì¤¿¤â¤Î¤Ç¤¢¤ë¡£¸½ºß¡¤¤³¤Îɽµ¤¬ÄêÃ夷¤Æ¤ª¤êÂè3ÈÇ¤Ç¤âÆ§½±¤¹¤ë¤³¤È¤È¤·¤¿¡£ ◉trauma, injury ¡¡Âè5¾Ï¤Ç¤Ï³°½ý¤Ë´ØÏ¢¤·¤¿ÍѸì¤È¤·¤Æ¡¤¡Ètrauma¡É¡Ètraumatic injury¡É¡Èinjury¡É¤ÎÍѸ줬»ÈÍѤµ¤ì¤Æ¤¤¤ë¡£¡Èinjury¡É¤Ï¡¤¼ê½ÑÁϤʤɳ°½ý°Ê³°¤Î¸¶°ø¤Ë¤è¤ë½ý¤â´Þ¤à¤¿¤á¡¤¸¶Â§¤È¤·¤Æ¡¤¡Ètrauma¡É¤ª¤è¤Ó¡Ètraumatic injury¡É¤Ë¤Ï¡Ö³°½ý¡×¤ò¡¤¡Èinjury¡É¤Ë¤Ï¡Ö½ý³²¡×¤ÎÌõ¤òÍѤ¤¤¿¡£¤¿¤À¤·¡¤Ê¸Ì®¤«¤éÌÀ¤é¤«¤Ë³°½ý¤Ë¤è¤ë½ý³²¤ò»Ø¤¹¡Èinjury¡É¤Ë¤Ï¡Ö³°½ý¡×¤ÎÌõ¸ì¤ò¤¢¤Æ¤¿¡£ ◉vasculopathy¤Èangiopathy¤ÎÌõ¸ì ¡¡Âè6¾Ï¤Ç¤Ï·ì´É¾ã³²¤Ë¤è¤ëƬÄˤ¬µºÜ¤µ¤ì¤Æ¤¤¤ë¡£¸¶Ê¸¤Ç¤Ï¡Èvasculopathy¡É¤È¡Èangiopathy¡É¤ÎξÊý¤¬»ÈÍѤµ¤ì¤Æ¤¤¤ë¤¬¡¤¤Û¤ÜƱµÁ¸ì¤Ç¤¢¤ê¡¤¤½¤ì¤¾¤ì¤ËÊ̤ÎÌõ¸ì¤ò¤¢¤Æ¤ë¤³¤È¤ÏÈò¤±¤Æ¤É¤Á¤é¤â¡Ö·ì´É¾É¡×¤È¤·¤¿¡£¤Þ¤¿¡Ö°ì²áÀ¶É½ê¿À·Ð¥¨¥Ô¥½¡¼¥É¡Êtransient focal neurologic episodes¡§TFNE¡Ë¡×¤Îά¾Î¡ÖTFNE¡×¤Ï±Ñ¸ì¸¶Ê¸¤Ë¤Ê¤¤¤¬¤¹¤Ç¤Ëɸ½àŪ¤Êά¸ì¤È¤·¤Æ»ÈÍѤµ¤ì¤Æ¤¤¤ë¤Î¤ÇÆüËܸìÈǤǤÏά¹æ¤òÄɵ¤·¤¿¡£ ◉6.2.2¡ÖÈó³°½ýÀ¤¯¤âËì²¼½Ð·ì¡ÊSAH¡Ë¤Ë¤è¤ëµÞÀƬÄˡפοÇÃǤˤĤ¤¤Æ ¡¡ICHD-3¦Â13¤Ë¤Ï¡ÖCT¤Ç¿ÇÃǤǤ¤Ê¤¤¾ì¹ç¡¤¹øÄÇÀü»É¤¬É¬¿Ü¤Ç¤¢¤ë¡×¡ÖMRI¤ÏSAH¤Î¿ÇÃÇŪ½é´ü¸¡ºº¤ÎŬ±þ¤Ç¤Ï¤Ê¤¤¡×¤ÈµºÜ¤µ¤ì¤Æ¤¤¤ë¡£¤ï¤¬¹ñ¤Ç¤ÏMRI¤ÎÉáµÚΨ¤¬¹â¤¯¡¤¶ÛµÞMRI¸¡ºº¤¬²Äǽ¤Ê»ÜÀߤ¬¾¯¤Ê¤¯¤Ê¤¤¡£T1¶¯Ä´²èÁü¡¤T2¶¯Ä´²èÁü¤Î¤ß¤Ç¤ÏƬ³¸Æâ½Ð·ì¤Î¿ÇÃǤϺ¤Æñ¤Ç¤¢¤ë¤¬¡¤FLAIR»£±Æ¤òÍѤ¤¤ì¤Ð½é´ü¿ÇÃǤȤ·¤ÆÍøÍѤ¹¤ë¤³¤È¤â²Äǽ¤Ç¤¢¤ê¡¤Å¬ÀڤʲèÁü¿ÇÃǤ¬¤Ê¤µ¤ì¤Æ¤¤¤ì¤Ð¡¤¿ñ±Õ¸¡ºº¤Ï¹Íθ¤ò¤·¤Æ¤âɬ¿Ü¤È¤Ï¸À¤¨¤Ê¤¤¤È¹Í¤¨¤é¤ì¤Æ¤¤¤ë¡£SAH¤Ë¤è¤ëƬÄˤοÇÃǤ˺ݤ·¤Æ¤Ï¡¤¡ØËýÀƬÄˤοÇÎÅ¥¬¥¤¥É¥é¥¤¥ó2013¡Ù¡Ê°å³Ø½ñ±¡¡Ë¤ÎCQI-3¡Ö¤¯¤âËì²¼½Ð·ì¤Ï¤É¤Î¤è¤¦¤Ë¿ÇÃǤ¹¤ë¤«¡×¡Ê9Êǡˤ⻲¾È¤¤¤¿¤À¤¤¿¤¤¡£ ◉6.8 Headache and¡¿or migraine-like aura attributed to chronic intracranial vasculopathy ¤ª¤è¤Ó10.1 Headache attributed to hypoxia and¡¿or hypercapnia ¤ÎÌõ¸ì ¡¡6.8 Headache and¡¿or migraine-like aura attributed to chronic intracranial vasculopathy ¤Ï6.8¡ÖËýÀƬ³¸Æâ·ì´É¾É¤Ë¤è¤ëƬÄˤ¢¤ë¤¤¤ÏÊÒÆ¬ÄËÍÍÁ°Ãû¡×¤È¤·¡¤10.1 Headache attributed to hypoxia and¡¿or hypercapnia ¤Ï10.1¡ÖÄã»ÀÁÇ·ì¾É¤¢¤ë¤¤¤Ï¹âú»À¥¬¥¹·ì¾É¤Ë¤è¤ëƬÄˡפȤ·¤¿¡£¡ÖA and¡¿or B¡×¤ÎËÝÌõ¤Ï¡ÖA¤Þ¤¿¤ÏB¡Ê¤¢¤ë¤¤¤Ï¤½¤ÎξÊý¡Ë¡×¤È¤¹¤ë¤³¤È¤¬¸¶Â§¤Ç¤¢¤ë¤¬¡¤¤³¤Î¸¶Â§¤Ë±è¤Ã¤Æ¡ÖËýÀƬ³¸Æâ·ì´É¾É¤Ë¤è¤ëƬÄˤޤ¿¤ÏÊÒÆ¬ÄËÍÍÁ°Ãû¡Ê¤¢¤ë¤¤¤Ï¤½¤ÎξÊý¡Ë¡×¡¤¡ÖÄã»ÀÁÇ·ì¾É¤Þ¤¿¤Ï¹âú»À¥¬¥¹·ì¾É¡Ê¤¢¤ë¤¤¤Ï¤½¤ÎξÊý¡Ë¤Ë¤è¤ëƬÄˡפȤ¹¤ë¤ÈÉÂ̾¤È¤·¤Æ¾éĹ¤È¤Ê¤ë¤³¤È¤«¤é¡Ö¤¢¤ë¤¤¤Ï¡×¤È´Êά²½¤·¤¿¡£ ◉intracranial neoplasia¤ÎÌõ¸ì ¡¡Âè7¾Ï¤Ë¤ª¤±¤ë¡Èintracranial neoplasia¡É¤ÎÌõ¸ì¤ò¡ÖƬ³¸Æâ¿·À¸Êª¡×¤ÈľÌõ¤¹¤ë¤«¡ÖǾ¼ðáç¡×¤È¤¹¤ë¤«¤Ë¤Ä¤¤¤Æ°Ñ°÷²ñÆâ¤ÇµÄÏÀ¤¬¤Ê¤µ¤ì¤¿¡£Âè3ÈÇbetaÈǤǤÏ7.4 Headache attributed to intracranial neoplasia ¤ò¡ÖƬ³¸Æâ¿·À¸Êª¤Ë¤è¤ëƬÄˡפÈÌõ¤·7.4.1 Headache attributed to intracranial neoplasm ¤ò¡ÖǾ¼ðáç¤Ë¤è¤ëƬÄˡפȤ·¤Æ¤¤¤¿¤¬¡¤¡Èneoplasia¡É¤È¡Èneoplasm¡É¤ÏƱµÁ¤Ç¤¢¤ë¤ÈȽÃǤ·¡¤Âè3ÈǤǤϤȤâ¤Ë¡ÖǾ¼ðáç¤Ë¤è¤ëƬÄˡפòÌõ¸ì¤È¤·¤ÆºÎÂò¤·¤¿¡£ ◉8.2 Medication-overuse headache¡ÊMOH¡Ë ¤ÎÌõ¸ì ¡¡8.2 Medication-overuse headache¡ÊMOH¡Ë ¤ÎÌõ¸ì¤È¤·¤ÆÂè3ÈÇbetaÈǤǤÏ8.2¡ÖÌôºÞ¤Î»ÈÍѲῤˤè¤ëƬÄË¡ÊÌôʪÍðÍÑÆ¬ÄË¡¤MOH¡Ë¡×¤òºÎÂò¤·¤¿¡£¤³¤ÎÊѹ¹¤Î·Ð°Þ¤äµÄÏÀ¤ÏÆüËÜÆ¬Ä˳زñ¤Îweb site¤Ë·ÇºÜ¤·¤Æ¤¤¤ë¡ÊURL¡§http://www.jhsnet.org/information/MOH_japanese_20140317.pdf¡Ë¡£Âè3ÈǤǤϳƾϤνé½Ð»þ¤Î¤ß8.2¡ÖÌôºÞ¤Î»ÈÍѲῤˤè¤ëƬÄË¡ÊÌôʪÍðÍÑÆ¬ÄË¡¤MOH¡Ë¡×¤Èɽµ¤·¡¤¤½¤ì°Ê¹ß¤Ï´Êά²½¤·¤Æ8.2¡ÖÌôºÞ¤Î»ÈÍѲῤˤè¤ëƬÄË¡ÊMOH¡Ë¡×¤È¤¹¤ë¤³¤È¤È¤·¤¿¡£ ◉MOH¤ÎÉþÌôÆü¿ô ¡¡8.2.6¡ÖñÆÈ¤Ç¤ÏÍðÍѤ˳ºÅö¤·¤Ê¤¤Ê£¿ô°åÌôÉʤˤè¤ëÌôʪÍðÍÑÆ¬ÄˡפÎÉþÌôÆü¿ô¤¬15Æü¤«¤é10Æü¤Ëû½Ì¤µ¤ì¤¿¤¬¡¤ËÝÌõ°Ñ°÷²ñ¤Ç15Æü¤Î¸í¿¢¤Ç¤Ï¤Ê¤¤¤«¤È¤Îµ¿µÁ¤¬½Ð¤µ¤ì¤¿¡£¤³¤Î¤¿¤á¡¤IHS¤ÎôÅö°Ñ°÷¤Ë¾È²ñ¤·¤¿¤¬¡¤10Æü¤ÇÀµ¤·¤¤¤È¤Î²óÅú¤òÆÀ¤¿¡£Êѹ¹¤·¤¿Íýͳ¤Ë¤Ä¤¤¤Æ¤Ï²óÅú¤¬ÆÀ¤é¤ì¤Æ¤¤¤Ê¤¤¡£ ◉11.8¡Ö·ÔÆÍÀå¹üð×ÂÓ±ê¤Ë¤è¤ëƬÄˤ¢¤ë¤¤¤Ï´éÌÌÄˡפοÇÃÇ´ð½à ¡¡¿ÇÃÇ´ð½àB¤Î¸¶Ê¸¤Ï¡¤¡ÖRadiological evidence of calcified or elongated stylohyoid ligament¡×¡ÊÀг¥²½¤¢¤ë¤¤¤Ï²áĹ¤Ê·ÔÆÍÀå¹üð×ÂӤβèÁü½ê¸«¤¬¤¢¤ë¡Ë¤ÈµºÜ¤µ¤ì¤Æ¤¤¤ë¡£¹ñÆâ¤ÎÀìÌç²È¤«¤éÂè3ÈÇbetaÈÇÆüËܸìÈǤËÂФ¹¤ë¥³¥á¥ó¥È¤È¤·¤Æ¡¤¡ÖRadiological evidence of calcified stylohyoid ligament or elongated styloid process¡×¡ÊÀг¥²½¤·¤¿·ÔÆÍÀå¹üð×ÂÓ¤¢¤ë¤¤¤Ï²áĹ¤Ê·Ô¾õÆÍµ¯¤Î²èÁü½ê¸«¤¬¤¢¤ë¡Ë¤¬Å¬ÀڤǤϤʤ¤¤«¤È¤Î¥³¥á¥ó¥È¤¬´ó¤»¤é¤ì¤Æ¤¤¤¿¡£ICHD-3¤Ë¤ª¤¤¤ÆµºÜ¤ÎÊѹ¹¤Ï¤Ê¤µ¤ì¤Æ¤ª¤é¤º¡¤Åö°Ñ°÷²ñ¤È¤·¤Æ¤Î·ëÏÀ¤âÆÀ¤Æ¤¤¤Ê¤¤¤¿¤á¡¤ËÝÌõ¤Ï¸¶Ê¸¤Ë±è¤Ã¤¿¤â¤Î¤È¤·¤¿¤¬¡¤½ÅÍפʻØÅ¦¤ÈȽÃǤ·Ëܹà¤ËÉÕµ¤¹¤ë¡£ ◉nuchal ridge¤Ë¤Ä¤¤¤Æ ¡¡¡Ènuchal¡É¤Ï¡Ö¹à¡Ê¤¦¤Ê¤¸¡Ë¡×¤ÈÌõ¤µ¤ì¤ë¤Î¤¬ÄÌÎã¤Ç¤¢¤ë¡£ICHD-3¤Ç»ÈÍѤµ¤ì¤Æ¤¤¤ë¡Ènuchal ridge¡É¤¬»Ø¤¹Éô°Ì¤¬¡¤ÆüËܸì¤Ç»ÈÍѤ¹¤ë¡Ö¹à¡Ê¤¦¤Ê¤¸¡Ë¡×¤¬»Ø¤¹Éô°Ì¤Îridge¡Êʬ¿åÎæ¡¿Î´µ¯¡Ë¤È²òÎ¥¤·¤Æ¤¤¤ë¤Î¤Ç¤Ï¤Ê¤¤¤«¤È¤Îµ¿µÁ¤¬°Ñ°÷²ñ¤ÇµÄÏÀ¤µ¤ì¤¿¡£¹ñºÝƬÄËʬÎà°Ñ°÷²ñôÅö°Ñ°÷¡¤Olesen°Ñ°÷Ĺ¤Ë¾È²ñ¤·¤¿¤È¤³¤í¡¤¡Ènuchal¡É¤Ïº¸±¦¤Î¼ª²ð¸åÊý¤Î³°¼ª¹¦¥ì¥Ù¥ë¤ò·ë¤Ö¥é¥¤¥ó¤«¤é²¼¤Î¼ó¤Î¸åÌ̤ò»Ø¤¹¤È¤Î²óÅú¤Ç¤¢¤Ã¤¿¡£ÆüËܸì¤Î¹à¡Ê¤¦¤Ê¤¸¡Ë¤Ï¼ó¤Î¸åÌ̤ÎÀµÃæÉôÉÕ¶á¤ò»Ø¤¹ÍѸì¤È¤·¤Æ»ÈÍѤµ¤ì¤ë¤³¤È¤¬Â¿¤¤¤¬¡¤¤³¤ì¤è¤ê¤Ï¹¤¤ÈϰϤò»Ø¤·¤Æ¤¤¤ë¤ÈÍý²ò¤µ¤ì¤ë¡£¡Ènuchal ridge¡É¤Ïȱ¤ÎÀ¸¤¨ºÝ¤ÎÉôʬ¤ò¼¨¤¹¤¤¤ï¤æ¤ë¶ß¤˳ºÅö¤¹¤ë¡Ê²¼¿Þ¡Ë¤¬¡¤ÍѸì¤È¤·¤Æ¤Ï¡Ö¹àÉô¾å±ï¡×¤ÈÌõ¤¹¤³¤È¤È¤·¤¿¡£ ¤ª¤ï¤ê¤Ë ¡¡ICHD-3¤ÏÀ¤³¦¤ÎƬÄˤ˴ؤ¹¤ëÃμ±¤Î·ë¾½¤Ç¤¢¤ë¡£ÆüËܸìÈǤò¸ø³«¤¹¤ë¤³¤È¤Ë¤è¤ê¡¤Æ¬Ä˰åÎŤ䯬Ä˸¦µæ¤Ë·È¤ï¤ë°å»Õ¡¤°åÎÅ´Ø·¸¼Ô¡¤¸¦µæ¼Ô¡¤¤µ¤é¤Ë¤Ï´µ¼Ô¡¤»Ô̱¤¬ºÇ¿·¤Î¹ñºÝƬÄËʬÎà¤Ë¥¢¥¯¥»¥¹¤¹¤ë¤³¤È¤¬²Äǽ¤È¤Ê¤ê¡¤¤ï¤¬¹ñ¤ÎƬÄ˰åÎÅ¤ÈÆ¬Ä˸¦µæ¤Î¼ÁŪ¸þ¾å¡¤¿þÌî¤Î¹¤¬¤ê¤¬²Ã®¤µ¤ì¤ë¤³¤È¤ò´üÂÔ¤¹¤ë¤â¤Î¤Ç¤¢¤ë¡£ ¡¡ËÝÌõ¤ËºÝ¤·¡¤¸¥¿ÈŪ¤ÊÅØÎϤòÀˤ·¤Þ¤º¤Ëºî¶È¤ò¤·¤Æ¤¤¤¿¤À¤¤¤¿°Ñ°÷¡¤´Ø·¸¼Ô¤ÎÊý¡¹¡¤¤½¤·¤Æ¡¤¤ªÌ¾Á°¤ò¾Ò²ð¤¹¤ë¤³¤È¤¬¤Ç¤¤Ê¤¤¤¬¡¤¤µ¤Þ¤¶¤Þ¤ÊΩ¾ì¤«¤éËÝÌõºî¶È¤Ë¤´¶¨ÎϤ¤¤¿¤À¤¤¤¿³§Íͤ˿´¤è¤ê´¶¼Õ¤ò¿½¤·¾å¤²¤ë¡£ ¡¡2018ǯ10·î ¡¡ÆüËÜÆ¬Ä˳زñ¡¦¹ñºÝƬÄËʬÎà°Ñ°÷²ñ ¡¡°Ñ°÷Ĺ¡¡ÃÝÅ翲ìÉ× ¡¡Éû°Ñ°÷Ĺ¡¡À¶¿å¡¡ÍøÉ§ ¸¶½ñÂè3ÈǤνøÊ¸ ¡¡¹ñºÝƬÄ˳زñ¤ÎʬÎà°Ñ°÷²ñ¤òÂåɽ¤·¤Æ¡¤¤³¤³¤Ë¹ñºÝƬÄËʬÎàÂè3ÈÇ¡ÊICHD-3¡Ë¤òȯɽ¤¹¤ë¤³¤È¤ò¸Ø¤ê¤Ë»×¤¦¡£ ¡¡¤³¤ì¤Ï2013ǯ¤ÎICHD-3 betaÈǤθå¤ò·Ñ¤°¤â¤Î¤Ç¤¢¤ë¡£betaÈǤÎÁÀ¤¤¤Ï¡¤ICHD-3¤ÎºÇ½ªÈǤò¸øÉ½¤¹¤ëÁ°¤Ë¤µ¤é¤Ê¤ë¼ÂÃϻ¤ò¿ä¿Ê¤¹¤ë¤³¤È¤Ç¤¢¤ê¡¤¤½¤·¤Æ¡¤¤½¤ì¤Ï¾å¼ê¤¯¹Ô¤Ã¤¿¡£¤È¤ê¤ï¤±¡¤Á°Ãû¤Î¤¢¤ëÊÒÆ¬ÄË¡¤·²È¯Æ¬ÄË¡¤ÆÃȯÀƬ³¸Æâ°µÐ¶¿Ê¾É¡¤»°ºµ¿À·ÐÄˤʤɤˤĤ¤¤Æ¡¤Í¥¤ì¤¿¼ÂÃϻ¸¦µæ¤¬È¯É½¤µ¤ì¤¿¡£Î㤨¤Ð¡¤A1.2¡ÖÁ°Ãû¤Î¤¢¤ëÊÒÆ¬ÄˡפÎÉÕÏ¿´ð½à¤Ï¡¤¤³¤Î¼À´µ¤ò°ì²áÀǾµõ·ìȯºî¤È¶èÊ̤¹¤ë¤¦¤¨¤Ç¡¤ICHD-3 betaÈÇËÜʸ¤Î1.2¡ÖÁ°Ãû¤Î¤¢¤ëÊÒÆ¬Äˡפδð½à¤è¤êÍ¥¤ì¤Æ¤¤¤ë¤³¤È¤¬Î©¾Ú¤µ¤ì¤Æ¤¤¤ë¡£3.1¡Ö·²È¯Æ¬ÄˡפοÇÃÇ´ð½àC1¤Î¿·µ¬´ØÏ¢¾É¾õ¤Ç¤¢¤Ã¤¿´éÌ̤ιÈĬ¤È¼ªÊÄ´¶¤Ï¡¤¼ÂÃϻ¤Ë¤è¤ê´ÕÊÌÅÀ¤Ç¤Ï¤Ê¤¤¤³¤È¤¬ÌÀ¤é¤«¤È¤Ê¤Ã¤¿¡£¤·¤¿¤¬¤Ã¤Æ¡¤¤³¤ì¤é¤Î¾É¾õ¤ÏICHD-3¤ÎÉÕÏ¿¤Î¤ß¤Ë¼ýÏ¿¤µ¤ì¤Æ¤ª¤ê¡¤¤µ¤é¤Ê¤ë¸¦µæ¤¬µá¤á¤é¤ì¤ë¡£¤³¤ì¤é¤¬¼À´µÊ¬Îà¤Îº¬µò¤Ë´ð¤Å¤¯¥×¥í¥»¥¹¤Î¹¥Îã¤Ç¤¢¤ë¡£º£¤ä¤³¤Î¥×¥í¥»¥¹¤Ï¡¤¾ÍèŪ¤Ë¹ñºÝƬÄËʬÎà¤Ë²Ã¤¨¤é¤ì¤ë¤¢¤é¤æ¤ëÊѹ¹¤ò²¼¤«¤é»Ù¤¨¤Æ¤¤¤ë¤â¤Î¤Ç¤¢¤ë¡£ ¡¡betaÈǤ¬ÍÍѤǤ¢¤ëÍýͳ¤Ï¡¤À¤³¦ÊÝ·òµ¡´Ø¡ÊWHO¡Ë¤«¤é¤Î¹ñºÝ¼ÀÉÂʬÎà²þÄûÂè11ÈÇ¡ÊICD-11¡Ë¤Î½ÐÈǤ˹ç¤ï¤»¡¤¤½¤Î¥³¡¼¥É¤ò´Þ¤ó¤ÇICHD-3¤Ë¼ýÏ¿¤Ç¤¤ë¤³¤È¤È¹Í¤¨¤é¤ì¤Æ¤¤¤¿¡£2016ǯ¤Ë¤ÏICD-11¤¬´°À®¤¹¤ë¤È¸«¹þ¤ó¤Ç¤¤¤¿¤¬¡¤»Äǰ¤Ê¤¬¤éͽ´ü¤·¤Ê¤¤Ä¹´ü¤ÎÃٱ䤬¤¢¤ê¡¤ºÇ½ª¥³¡¼¥É¤Ï°ÍÁ³¤È¤·¤ÆÍøÍÑÉÔ²Äǽ¤Ç¤¢¤ë¡£¤½¤Î¤¿¤á¡¤ºÇ½ª¥³¡¼¥ÉÈ´¤¤ÇICHD-3¤ò¸øÉ½¤·¤Ê¤±¤ì¤Ð¤Ê¤é¤Ê¤¤¡£ ¡¡¸½ºßICHD-I¤È¸Æ¤Ð¤ì¤ë¹ñºÝƬÄËʬÎà½éÈǤÎȯɽ¤«¤é¡¤¤Á¤ç¤¦¤É30ǯ¸å¤Ë¡ØCephalalgia¡Ù»ï2018ǯÂè1¹æ¤ÇICHD-3¤¬½ÐÈǤµ¤ì¤¿¡£½éÈǤϼç¤ËÀìÌç²È¤Î¸«²ò¤Ë´ð¤Å¤¯¤â¤Î¤Ç¤¢¤Ã¤¿¤¬¡¤¤½¤ì¤Ç¤âÂçÉôʬ¤¬Í¸ú¤Ç¤¢¤ë¤³¤È¤¬¾ÚÌÀ¤µ¤ì¤¿¡£2004ǯ¤Ëȯɽ¤µ¤ì¤¿ICHD-2¤Ë¤Ï¡¤¿·¤¿¤Êº¬µò¤ÈÀìÌç²È¤Ë¤è¤ë¸«²ò¤Î¸«Ä¾¤·¤Ë´ð¤Å¤¯Â¿¿ô¤ÎÊѹ¹¤¬À¹¤ê¹þ¤Þ¤ì¤¿¡£¿·¤¿¤Ê²Ê³ØÅªº¬µò¤¬¡¤ICHD-3 betaÈǤ˲䨤é¤ì¤¿Êѹ¹¤Ç¤ÏÈæ³ÓŪÂ礤ÊÌò³ä¤ò²Ì¤¿¤·¤¿¤¬¡¤ICHD-3¤Ë¤ª¤±¤ë¤µ¤é¤Ê¤ëÊѹ¹¤â¤¹¤Ù¤Æ¤³¤¦¤¤¤Ã¤¿º¬µò¤Ë´ð¤Å¤¤¤Æ¤¤¤ë¡£¤³¤Î¤è¤¦¤Ë¡¤¸½ºß¤ª¤è¤Óº£¸å¤ÎƬÄËʬÎà¤Ï¡¤´°Á´¤Ë¸¦µæ¤Ë´ð¤Å¤¤¤Æ¤¤¤ë¡£ ¡¡2010ǯ¤Ë»Ï¤Þ¤Ã¤¿Ä¹¤¤Æ»¤Î¤ê¤ÏICHD-3¤Îȯɽ¤Ë¤è¤Ã¤Æ½ªÎ»¤·¤¿¤¬¡¤¸½¹Ô¤Î°Ñ°÷²ñ¤Ë¤Ï¤Þ¤À¤³¤ì¤«¤é¤Î¿ôǯ´Ö¤Ë¤Ê¤¹¤Ù¤¤³¤È¤¬Â¿¤¯¤¢¤ë¡£ICHD-3 betaÈǤÏ¿¤¯¤Î¸À¸ì¤ËËÝÌõ¤µ¤ì¤¿¤¬¡¤³Æ¸À¸ì¤ÇICHD-3¤ò¸øÉ½¤¹¤ëÁ°¤Ë¡¤¤³¤ì¤éËÝÌõ¤ò¹¹¿·¤¹¤ëɬÍפ¬¤¢¤ë¡£ICHD-3¤¬¤¹¤Ù¤Æ¤Î¼çÍ׸À¸ì¤È¿¤¯¤Î¾¯¿ô¸À¸ì¤Ç¤âÍøÍѲÄǽ¤È¤Ê¤ë¤è¤¦¡¤Â¿¤¯¤ÎÄɲÃËÝÌõ¤¬È¯É½¤µ¤ì¤ë¤³¤È¤ò´üÂÔ¤·¤¿¤¤¡£Hartmut Göbel¶µ¼ø¼çƳ¤Î¤â¤ÈºîÀ®¤µ¤ì¤Æ¤¤¤¿ICHD-3 betaÈǤÎÅÅ»ÒÈǤ⡤ICHD-3¤Ë¹¹¿·¤µ¤ì¤ëͽÄê¤Ç¤¢¤ë¡£Morris Levin¶µ¼ø¤ÈJes Olesen¶µ¼ø¤¬¶¦Æ±¤Ç¾ÉÎ㽸¤ÎºîÀ®¤ò·×²è¤·¤Æ¤¤¤ë¡£ºÇ½ªÅª¤Ë¡¤ICD-11¤Î¥³¡¼¥É¤¬ÍøÍѲÄǽ¤È¤Ê¤ê¼¡Â衤Timothy Steiner¶µ¼ø¤ÈJes Olesen¶µ¼ø¤¬ICHD-3¤ÈWHO¤ÎICD-11¤Î¶¶ÅϤ·¤ò¹Ô¤¦Í½Äê¤Ç¤¢¤ë¡£ ¡¡¤½¤ì¤Ç¤Ï¡¤Æ¬ÄËʬÎà¤Î¾Íè¤Ï¤É¤Î¤è¤¦¤Ë¤Ê¤ë¤Î¤À¤í¤¦¤«¡£Ê¬Îà¤Ï¸¶Â§¤È¤·¤ÆÊݼéŪ¤Ç¤Ê¤±¤ì¤Ð¤Ê¤é¤Ê¤¤¡£Ê¬Îà¤ËÂçÉý¤ÊÊѹ¹¤ò²Ã¤¨¤¿¾ì¹ç¡¤¤½¤ÎʬÎà¤ÎÊѹ¹¤µ¤ì¤¿Éôʬ¤Ç°úÍѤ·¤Æ¤¤¤¿¤¹¤Ù¤Æ¤ÎÀè¹Ô¸¦µæ¤ò¸«Ä¾¤µ¤Ê¤±¤ì¤Ð¤Ê¤é¤Ê¤¤¡£Î㤨¤Ð¡¤¿ÇÃÇ´ð½à¤ËÂçÉý¤ÊÊѹ¹¤¬²Ã¤¨¤é¤ì¤¿¾ì¹ç¡¤¿·µ¬¤Î¿ÇÃǤÇʬÎव¤ì¤ë´µ¼Ô¤È°ÊÁ°¤Î¿ÇÃǤÇʬÎव¤ì¤ë´µ¼Ô¤¬°Û¤Ê¤Ã¤Æ¤¯¤ë¤¿¤á¡¤°ÊÁ°¤Î¿ÇÃÇ´ð½à¤Ë´ð¤Å¤¤¤Æ¼Â»Ü¤µ¤ì¤¿Ìôʪ»î¸³¤ÏºÆÅټ»ܤ·Ä¾¤µ¤Ê¤±¤ì¤Ð¤Ê¤é¤Ê¤¤¡£¾ÍèŪ¤ÊÊѹ¹¤¬´°Á´¤Ëº¬µò¤Ë´ð¤Å¤¤¤¿¤â¤Î¤È¤Ê¤ë¤è¤¦¡¤ICHD-3¤Ç¹Ô¤ï¤ì¤¿³èȯ¤Ê¼ÂÃϻ¤È²Ê³ØÅªÊ¬ÀϤ¬º£¸å¤â·Ñ³¤¹¤ë¤³¤È¤¬´üÂÔ¤µ¤ì¤ë¡£´·Îã¤Ë½¾¤¨¤Ð¡¤ICHD-4¤Îȯɽ¤Ï10¡Á15ǯ¸å¤È¤Ê¤ë¤¬¡¤¤½¤Î´Ö¤Ë¤Ï¿¤¯¤Î¼ÂÃϻ¸¦µæ¤¬¹Ô¤ï¤ì¤ë¤À¤í¤¦¡£ICHD-2¤ÎÊѹ¹¤µ¤ì¤¿¿ÇÃÇ´ð½à¤È¤·¤Æ1.3¡ÖËýÀÊÒÆ¬Äˡפ¬¡ØCephalalgia¡Ù»ï¤Ëȯɽ¤µ¤ì¤¿¤¬¡¤¤³¤ì¤é¤ÎÊѹ¹¤ÏʬÎà°Ñ°÷²ñ¤Ë¤è¤Ã¤Æ¾µÇ§¤µ¤ì¡¤¿ôǯ¸å¤ËICHD-3 betaÈǤ¬Åо줹¤ë¤Þ¤Ç¹ñºÝƬÄËʬÎà¤Ë¤ÏÅý¹ç¤µ¤ì¤Ê¤«¤Ã¤¿¤â¤Î¤Î¡¤Ä¾¤Á¤Ë»ÈÍѤò³«»Ï¤¹¤ë¤è¤¦¤Ëµá¤á¤é¤ì¤¿¡£¾Íè¤ÎƬÄËʬÎà°Ñ°÷²ñ¤âƱÍͤˡ¤¡ØCephalalgia¡Ù»ï¤Çȯɽ¤µ¤ì¤¿Í¥¤ì¤¿¼ÂÃϻ¸¦µæ¤Ë¤è¤Ã¤Æ¿·µ¬¤Þ¤¿¤Ï²þÄû¿ÇÃÇ´ð½à¤¬Î©¾Ú¤µ¤ì¤¿¾ì¹ç¤Ë¤Ï¡¤¤½¤ì¤é¤ÎºÎÂò¤òICHD-4¤ÎȯɽÁ°¤Ë¾µÇ§¤ª¤è¤Ó»Ù»ý¤Ç¤¤ë¤è¤¦¤Ë¤¹¤Ù¤¤Ç¤¢¤ë¡£ ¡¡ICHD-1¤Ï¡¤Æ¬ÄËʬÎà¤ò¿À·Ð¼À´µ¤Î¤Ê¤«¤ÇºÇ°¤ÎʬÎफ¤éºÇÎɤÎʬÎà¤Ø¤ÈƳ¤¤¤¿¡£¤³¤ÎÀª¤¤¤Ï30ǯ´Ö°Ý»ý¤µ¤ì¡¤¤½¤·¤ÆºÇ¶á¡¤¥¸¥å¥Í¡¼¥Ö¤Ë¤ª¤±¤ëICD-11¿À·ÐÉôÌç¤Î°Ñ°÷²ñºî¶È¤Î¤Ê¤«¤ÇƬÄËʬÎà¤ÎÍ¥°ÌÀ¤¬ÌÀ¤é¤«¤È¤Ê¤Ã¤¿¡£¿À·ÐʬÌî¤Ë¤ª¤¤¤Æ¡¤¤¹¤Ù¤Æ¤Î¼À´µ¤òÌÀÇò¤Ê¿ÇÃÇ´ð½à¤Ç¤³¤Î¤è¤¦¤ËÂηÏŪ¤ËʬÎष¤¿¤â¤Î¤Ï¤Û¤«¤Ë¤Ê¤¤¡£¤³¤Î´·Î㤬º£¸å¤â°Ý»ý¤µ¤ì¡¤Æ¬Äˤ¬¿À·Ð¼À´µ¤ÎʬÎà¤Ë¤ª¤¤¤Æ°ú¤Â³¤ÀèÆ³¤·Â³¤±¤ë¤³¤È¤òÀڤ˴ê¤Ã¤Æ¤¤¤ë¡£ ¡¡Jes Olesen ¡¡¹ñºÝƬÄ˳زñ ¡¡Æ¬ÄËʬÎà°Ñ°÷²ñ ¡¡°Ñ°÷Ĺ ¼Õ¼ ¡¡¹ñºÝƬÄ˳زñ¤ÎƬÄËʬÎà°Ñ°÷²ñ¤Îºî¶È¤Ï¡¤¹ñºÝƬÄ˳زñ¤Î¤ß¤Ë¤è¤ë·ÐºÑŪ¤Ê±ç½õ¤ò¼õ¤±¤Æ¹Ô¤ï¤ì¤Æ¤¤¤ë¡£¡Ø¹ñºÝƬÄËʬÎàÂè3Èǡ٤ˤϾ¦¶ÈŪ¥¹¥Ý¥ó¥µ¡¼¤Ï¸ºß¤·¤Ê¤¤¡£Timothy Steiner¤Î¶¨ÎϤ˴¶¼Õ¤¹¤ë¡£Âè°ì¤ËʬÎà°Ñ°÷²ñ¤Î̾ÍÀ´´»ö¤È¤·¤Æ¤Î¿ÔÎϤËÂФ·¤Æ¡¤¼¡¤¤¤ÇËܹƤθ¶¹ÆÀ°Íý¤ª¤è¤Ó½àÈ÷¤Ë¤ª¤±¤ëÈà¤Î»Å»ö¤ËÂФ·¤Æ¡£
ÆüËÜÆ¬Ä˳زñ¡¦¹ñºÝƬÄËʬÎà°Ñ°÷²ñ°Ñ°÷°ìÍ÷ ¹ñºÝƬÄ˳زñ¡¦Æ¬ÄËʬÎà°Ñ°÷²ñ°Ñ°÷°ìÍ÷ ¹ñºÝƬÄËʬÎà¡¡Âè3ÈǤΥ¥¥ó¥°¥°¥ë¡¼¥× ¹ñºÝƬÄËʬÎà¡¡Âè3ÈÇ¡ÊICHD-3¡ËÆüËܸìÈÇ¤Ë´ó¤»¤Æ ¹ñºÝƬÄËʬÎà¡¡Âè3ÈÇ¡ÊICHD-3¡ËÆüËܸìÈÇ¡¡ºîÀ®¤Ë¤¢¤¿¤Ã¤Æ ¿·¹ñºÝƬÄËʬÎà¡ÊICHD-II¡ËÆüËܸìÈÇ¡¡ËÝÌõ¤Ë¤¢¤¿¤Ã¤Æ ¸¶½ñÂè3ÈǤνøÊ¸ ¸¶½ñÂè1ÈǤνøÊ¸ ¤³¤ÎʬÎà¤Î»È¤¤Êý ¹ñºÝƬÄËʬÎà Âè1Éô¡¡°ì¼¡ÀƬÄË ¡¡1¡¥ÊÒÆ¬ÄË ¡¡2¡¥¶ÛÄ¥·¿Æ¬ÄË ¡¡3¡¥»°ºµ¿À·Ð¡¦¼«Î§¿À·ÐÀƬÄË¡ÊTACs¡Ë ¡¡4¡¥¤½¤Î¾¤Î°ì¼¡ÀƬÄ˼À´µ Âè2Éô¡¡Æó¼¡ÀƬÄË ¡¡Æó¼¡ÀƬÄˤνï¸À ¡¡5¡¥Æ¬ðôÉô³°½ý¡¦½ý³²¤Ë¤è¤ëƬÄË ¡¡6¡¥Æ¬ðôÉô·ì´É¾ã³²¤Ë¤è¤ëƬÄË ¡¡7¡¥Èó·ì´ÉÀƬ³¸Æâ¼À´µ¤Ë¤è¤ëƬÄË ¡¡8¡¥Êª¼Á¤Þ¤¿¤Ï¤½¤ÎΥæ¤Ë¤è¤ëƬÄË ¡¡9¡¥´¶À÷¾É¤Ë¤è¤ëƬÄË ¡¡10¡¥¥Û¥á¥ª¥¹¥¿¡¼¥·¥¹¾ã³²¤Ë¤è¤ëƬÄË ¡¡11¡¥Æ¬³¸¹ü¡¤ðô¡¤´ã¡¤¼ª¡¤É¡¡¤ÉûÉ¡¹Ð¡¤»õ¡¤¸ý¤¢¤ë¤¤¤Ï¤½¤Î¾¤Î´éÌÌ¡¦ðôÉô¤Î ¡¡¡¡¡¡¡¡¡¡¹½À®ÁÈ¿¥¤Î¾ã³²¤Ë¤è¤ëƬÄˤޤ¿¤Ï´éÌÌÄË ¡¡12¡¥Àº¿À¼À´µ¤Ë¤è¤ëƬÄË Âè3Éô¡¡ÍÄËÀǾ¿À·Ð¥Ë¥å¡¼¥í¥Ñ¥Á¡¼¡¤Â¾¤Î´éÌÌÄˤª¤è¤Ó¤½¤Î¾¤ÎƬÄË ¡¡13¡¥Ç¾¿À·Ð¤ÎÍÄËÀÉÂÊѤª¤è¤Ó¤½¤Î¾¤Î´éÌÌÄË ¡¡14¡¥¤½¤Î¾¤ÎƬÄËÀ¼À´µ ÉÕÏ¿ ÍѸì¤ÎÄêµÁ º÷°ú |
||||||||||||||||||||||||||||||||||||||||||

- >
- ·ò¹¯¤È°å³Ø
- >
- ɵ¤¡¢¾É¾õ
- >
- »Ò¤É¤â¤Îɵ¤







¾åµ¤ÎʸÀդϡ¢Áí¤Æ»ä¤Ëͤê¤Þ¤¹¡£
¤´¼«Í³¤Ë¡¢¤´»ÈÍѲ¼¤µ¤¤¡£
¤¢¤ê¤¬¤È¤¦¤´¤¶¤¤¤Þ¤¹¡£
žºÜ¤Ï¡¢¸æ¼«Í³¤Ç¤¹¡£ (°ìÉôžºÜ¤â¸æ¼«Í³¤Ç¤¹)
¤ß¤ó¤Ê¤¬¡¢¤¤¤ÁÁ᤯¡¢½õ¤«¤ê¤Þ¤¹Íͤˡ¦¡¦¡¦¡¦¡¦¡¦
2019/2/10(Æü) ¸á¸å 8:01 [ £Ë£É£Ë£É£Ô£Á£Ô£Á ]
Ãí¡§µºÜ¤Ë¸í¤ê¤¬¤¢¤ì¤Ð¡¢±óθ̵¤¯¤´¶µ¼¨²¼¤µ¤¤¡£
ÈãȽ¡¦·ãÎ塦ʸ¶ç¡¤¤Ê¤ó¤Ç¤â´¿·Þ
¤ß¤ó¤Ê¤¬¡¢¤¤¤ÁÁ᤯¡¢½õ¤«¤ê¤Þ¤¹Íͤˡ¦¡¦¡¦¡¦¡¦
2019/2/10(Æü) ¸á¸å 8:03 [ £Ë£É£Ë£É£Ô£Á£Ô£Á ]